Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Lung Cancer

Free Subscription Articles published in J Cancer Res Clin Oncol Retrieve available abstracts of 338 articles: HTML format

Single Articles

April 2024
1. WU X, Zhao X, Zhou C, Wei N, et al
   Prognostic and onco-immunological value of immune-related eRNAs-driven genes in lung adenocarcinoma.
   J Cancer Res Clin Oncol. 2024;150:188.
   PubMed     Abstract available
   
   
   
2. HONG S, Lee JH, Heo JY, Suh KJ, et al
   Impact of concurrent medications on clinical outcomes of cancer patients treated with immune checkpoint inhibitors: analysis of Health Insurance Review and Assessment data.
   J Cancer Res Clin Oncol. 2024;150:186.
   PubMed     Abstract available
   
   
   
3. WANG Y, Lyu D, Cheng C, Zhou T, et al
   Preoperative nomogram for predicting spread through air spaces in clinical-stage IA non-small cell lung cancer using (18)F-fluorodeoxyglucose positron emission tomography/computed tomography.
   J Cancer Res Clin Oncol. 2024;150:185.
   PubMed     Abstract available
   
   
   
4. ZHAO R, Guan X, Zhang P, Liu Y, et al
   Development of postoperative bronchopleural fistula after neoadjuvant immunochemotherapy in non-small cell lung cancer: case reports and review of the literature.
   J Cancer Res Clin Oncol. 2024;150:175.
   PubMed     Abstract available
   
   
   
5. SAKASHITA M, Motoi N, Yamamoto G, Gambe E, et al
   An algorithm-based technique for counting mitochondria in cells using immunohistochemical staining of formalin-fixed and paraffin-embedded sections.
   J Cancer Res Clin Oncol. 2024;150:172.
   PubMed     Abstract available
   
   
   March 2024
6. JIANG L, Yang P, Liu Y, Li J, et al
   BRAF/MEK-targeted therapy in BRAF ex15 p.T599dup mutation-driven NSCLC: a case report.
   J Cancer Res Clin Oncol. 2024;150:162.
   PubMed     Abstract available
   
   
   
7. BANAT M, Potthoff AL, Hamed M, Borger V, et al
   Synchronous versus metachronous spinal metastasis: a comparative study of survival outcomes following neurosurgical treatment.
   J Cancer Res Clin Oncol. 2024;150:136.
   PubMed     Abstract available
   
   
   
8. GE Y, Zhan Y, He J, Li J, et al
   PD-(L)1 inhibitors plus bevacizumab and chemotherapy as first-line therapy in PD-L1-negative metastatic lung adenocarcinoma: a real-world data.
   J Cancer Res Clin Oncol. 2024;150:135.
   PubMed     Abstract available
   
   
   
9. JU W, Lin L, Zhang Q, Lv X, et al
   GATA6 inhibits the biological function of non-small cell lung cancer by modulating glucose metabolism.
   J Cancer Res Clin Oncol. 2024;150:126.
   PubMed     Abstract available
   
   
   
10. SHIJUBOU N, Sumi T, Kubo T, Sasaki K, et al
    Prognostic significance of immunohistochemical classification utilizing biopsy specimens in patients with extensive-disease small-cell lung cancer treated with first-line chemotherapy and immune checkpoint inhibitors.
    J Cancer Res Clin Oncol. 2024;150:125.
    PubMed     Abstract available
    
    
    
11. MA M, Luo M, Liu Q, Zhong D, et al
    Influence of abdominal fat distribution and inflammatory status on post-operative prognosis in non-small cell lung cancer patients: a retrospective cohort study.
    J Cancer Res Clin Oncol. 2024;150:111.
    PubMed     Abstract available
    
    
    February 2024
12. KRIZOVA L, Benesova I, Zemanova P, Spacek J, et al
    Immunophenotyping of peripheral blood in NSCLC patients discriminates responders to immune checkpoint inhibitors.
    J Cancer Res Clin Oncol. 2024;150:99.
    PubMed     Abstract available
    
    
    
13. WANG Y, Dong A, Jin M, Li S, et al
    TEP RNA: a new frontier for early diagnosis of NSCLC.
    J Cancer Res Clin Oncol. 2024;150:97.
    PubMed     Abstract available
    
    
    
14. NIU L, Wu H, Gao R, Chen L, et al
    Optimal sequence of LT for symptomatic BM in EGFR-mutant NSCLC: a comparative study of first-line EGFR-TKIs with/without upfront LT.
    J Cancer Res Clin Oncol. 2024;150:94.
    PubMed     Abstract available
    
    
    
15. KURIBAYASHI T, Ohashi K, Nishii K, Ninomiya K, et al
    Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study.
    J Cancer Res Clin Oncol. 2024;150:89.
    PubMed     Abstract available
    
    
    
16. ZHOU W, Yeerkenbieke G, Zhang Y, Zhou M, et al
    Guanylate binding protein 4 shapes an inflamed tumor microenvironment and identifies immuno-hot tumors.
    J Cancer Res Clin Oncol. 2024;150:90.
    PubMed     Abstract available
    
    
    
17. XIA X, Ge Y, Ge F, Gu P, et al
    MAP4 acts as an oncogene and prognostic marker and affects radioresistance by mediating epithelial-mesenchymal transition in lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2024;150:88.
    PubMed     Abstract available
    
    
    
18. FAN X, Zhang Q, Qin S, Ju S, et al
    CircBRIP1: a plasma diagnostic marker for non-small-cell lung cancer.
    J Cancer Res Clin Oncol. 2024;150:83.
    PubMed     Abstract available
    
    
    
19. DU C, Tan L, Xiao X, Xin B, et al
    Detection of the DNA methylation of seven genes contribute to the early diagnosis of lung cancer.
    J Cancer Res Clin Oncol. 2024;150:77.
    PubMed     Abstract available
    
    
    
20. WU Y, Zhang J, Zhou W, Yuan Z, et al
    Prognostic factors in extensive-stage small cell lung cancer patients with organ-specific metastasis: unveiling commonalities and disparities.
    J Cancer Res Clin Oncol. 2024;150:74.
    PubMed     Abstract available
    
    
    
21. CHENG X, Zhou J, Chen Y, Zhao Y, et al
    Patterns and trends of mortality from metastatic colorectal cancer in Shanghai, China from 2005 to 2021: a population-based retrospective analysis.
    J Cancer Res Clin Oncol. 2024;150:68.
    PubMed     Abstract available
    
    
    January 2024
22. LIANG Y, Zhang X, Peng J, Liu J, et al
    Vitamin D-mediated tsRNA-07804 triggers mitochondrial dysfunction and suppresses non-small cell lung cancer progression by targeting CRKL.
    J Cancer Res Clin Oncol. 2024;150:51.
    PubMed     Abstract available
    
    
    
23. ZHANG H, Lin J, Yahaya BH
    Comprehensive analysis of co-expressed genes with TDP-43: prognostic and therapeutic potential in lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2024;150:44.
    PubMed     Abstract available
    
    
    
24. CUI Y, Lin J, Sun D, Zhang H, et al
    Nomogram for predicting the overall survival and cancer-specific survival of patients with intraductal carcinoma of the prostate.
    J Cancer Res Clin Oncol. 2024;150:45.
    PubMed     Abstract available
    
    
    
25. WANG X, He J, Li J, Wu C, et al
    Concordance of assessments of four PD-L1 immunohistochemical assays in esophageal squamous cell carcinoma (ESCC).
    J Cancer Res Clin Oncol. 2024;150:43.
    PubMed     Abstract available
    
    
    
26. ZHANG J, Han W, Guo J, Zhang C, et al
    Efficacy of immunotherapy in HER2-mutated non-small cell lung cancer: a single-arm meta-analysis.
    J Cancer Res Clin Oncol. 2024;150:42.
    PubMed     Abstract available
    
    
    
27. YUCE TH, Ak G, Metintas S, Dundar E, et al
    BAP1, Wilms' tumor 1, and calretinin in predicting survival and response to first-line chemotherapy in patients with pleural mesothelioma.
    J Cancer Res Clin Oncol. 2024;150:38.
    PubMed     Abstract available
    
    
    
28. HUANG BT, Wang Y, Lin PX
    Developing a clinical-radiomic prediction model for 3-year cancer-specific survival in lung cancer patients treated with stereotactic body radiation therapy.
    J Cancer Res Clin Oncol. 2024;150:34.
    PubMed     Abstract available
    
    
    
29. LIU JJ, Shen WB, Qin QR, Li JW, et al
    Prediction of positive pulmonary nodules based on machine learning algorithm combined with central carbon metabolism data.
    J Cancer Res Clin Oncol. 2024;150:33.
    PubMed     Abstract available
    
    
    
30. LU J, Feng Y, Guo K, Sun L, et al
    Prognostic value of preoperative circulating tumor DNA in non-small cell lung cancer: a systematic review and meta-analysis.
    J Cancer Res Clin Oncol. 2024;150:25.
    PubMed     Abstract available
    
    
    
31. ZHU L, Qin J
    Predictive biomarkers for immunotherapy response in extensive-stage SCLC.
    J Cancer Res Clin Oncol. 2024;150:22.
    PubMed     Abstract available
    
    
    
32. MENG X, Zhao X, Zhou B, Song W, et al
    FSTL3 is associated with prognosis and immune cell infiltration in lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2024;150:17.
    PubMed     Abstract available
    
    
    
33. XU J, Chen H, Fan W, Qiu M, et al
    Plasma cell-free DNA as a sensitive biomarker for multi-cancer detection and immunotherapy outcomes prediction.
    J Cancer Res Clin Oncol. 2024;150:7.
    PubMed     Abstract available
    
    
    December 2023
34. BAI Y, Liu Y, Wu J, Miao R, et al
    CD4 levels and NSCLC metastasis: the benefits of maintaining moderate levels.
    J Cancer Res Clin Oncol. 2023;149:16827-16836.
    PubMed     Abstract available
    
    
    
35. ZHANG W, He Z, Liang F, Gong J, et al
    Albendazole induces an anti-tumor effect and potentiates PD-L1 blockade immunotherapy.
    J Cancer Res Clin Oncol. 2023;149:16763-16778.
    PubMed     Abstract available
    
    
    
36. LU Y, Li Q, Xu L, Zheng Y, et al
    Thyroid dysfunction induced by anti-PD-1 therapy is associated with a better progression-free survival in patients with advanced carcinoma.
    J Cancer Res Clin Oncol. 2023;149:16501-16510.
    PubMed     Abstract available
    
    
    
37. YI M, Shi J, Tan X, Zhang X, et al
    Integration and deconvolution methodology deciphering prognosis-related signatures in lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2023;149:16441-16460.
    PubMed     Abstract available
    
    
    
38. LIU W, Xia J, Du Q, Wang J, et al
    Clinico-pathological characteristics of IGFR1 and VEGF-A co-expression in early and locally advanced-stage lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2023;149:16365-16376.
    PubMed     Abstract available
    
    
    
39. MENG X, Song W, Zhou B, Liang M, et al
    Prognostic and immune correlation analysis of mitochondrial autophagy and aging-related genes in lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2023;149:16311-16335.
    PubMed     Abstract available
    
    
    
40. ZHANG J, Song L, Li G, Liang A, et al
    Comprehensive assessment of base excision repair (BER)-related lncRNAs as prognostic and functional biomarkers in lung adenocarcinoma: implications for personalized therapeutics and immunomodulation.
    J Cancer Res Clin Oncol. 2023;149:17199-17213.
    PubMed     Abstract available
    
    
    
41. SHIRAISHI S, Sugimoto M, Tokuuye K
    Salivary metabolites as novel independent predictors of radiation pneumonitis.
    J Cancer Res Clin Oncol. 2023;149:17559-17566.
    PubMed     Abstract available
    
    
    November 2023
42. XU M, Hao Y, Shi Z, Song Z, et al
    Efficacy of rechallenge immunotherapy after immune monotherapy resistance in patients with advanced non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2023 Nov 17. doi: 10.1007/s00432-023-05490.
    PubMed     Abstract available
    
    
    
43. XIONG Y, Gu F, Cui J, Liu Y, et al
    Construction and validation of a novel prognostic nomogram for predicting overall survival in lung adenocarcinoma patients with different patterns of metastasis.
    J Cancer Res Clin Oncol. 2023;149:15039-15053.
    PubMed     Abstract available
    
    
    
44. LV H, Shao Y, Chen QS, Song WJ, et al
    A case of endobronchial metastasis of colon cancer mimics sarcoidosis, and a review of related literature.
    J Cancer Res Clin Oncol. 2023;149:15287-15292.
    PubMed     Abstract available
    
    
    
45. LIU J, Wei L
    Construction and validation of an efferocytosis-related prognostic signature in lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2023;149:14577-14596.
    PubMed     Abstract available
    
    
    
46. WANG Y, Yan C, Zhang C, Yu E, et al
    The disappearance of gastric metastasis and liver metastasis in non-small cell lung adenocarcinoma is due to osimertinib.
    J Cancer Res Clin Oncol. 2023;149:16069-16073.
    PubMed     Abstract available
    
    
    
47. ZHOU J, Fang P, Liang Z, Li X, et al
    Causal relationship between lung diseases and risk of esophageal cancer: insights from Mendelian randomization.
    J Cancer Res Clin Oncol. 2023;149:15679-15686.
    PubMed     Abstract available
    
    
    
48. ZHANG G, Guan H, Ning YL, Yao K, et al
    Osimertinib resistance prognostic gene signature: STRIP2 is associated with immune infiltration and tumor progression in lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2023;149:15573-15588.
    PubMed     Abstract available
    
    
    
49. MILJANIC M, Nwachukwu C, Rahimi A
    Definitive ablative stereotactic partial breast irradiation in early stage inoperable breast cancer.
    J Cancer Res Clin Oncol. 2023;149:15553-15559.
    PubMed     Abstract available
    
    
    
50. CHANG Y, Xing H, Shang Y, Liu Y, et al
    Preoperative predicting invasiveness of lung adenocarcinoma manifesting as ground-glass nodules based on multimodal images of dual-layer spectral detector CT radiomics models.
    J Cancer Res Clin Oncol. 2023;149:15425-15438.
    PubMed     Abstract available
    
    
    
51. GAO R, Gao Y, Zhang J, Zhu C, et al
    A nomogram for predicting invasiveness of lung adenocarcinoma manifesting as pure ground-glass nodules: incorporating subjective CT signs and histogram parameters based on artificial intelligence.
    J Cancer Res Clin Oncol. 2023;149:15323-15333.
    PubMed     Abstract available
    
    
    October 2023
52. KUBO S, Kobayashi N, Matsumoto H, Somekawa K, et al
    Atezolizumab addition to platinum doublet: evaluating survival outcomes for patients with extensive disease small cell lung cancer.
    J Cancer Res Clin Oncol. 2023 Oct 25. doi: 10.1007/s00432-023-05457.
    PubMed     Abstract available
    
    
    
53. MOREIRA RS, da Silva MM, de Melo Vasconcelos CF, da Silva TD, et al
    Siglec 15 as a biomarker or a druggable molecule for non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2023 Oct 16. doi: 10.1007/s00432-023-05437.
    PubMed     Abstract available
    
    
    
54. YIN T, Liu K, Shen Y, Wang Y, et al
    Alteration of serum bile acids in non-small cell lung cancer identified by a validated LC-MS/MS method.
    J Cancer Res Clin Oncol. 2023 Oct 10. doi: 10.1007/s00432-023-05434.
    PubMed     Abstract available
    
    
    
55. LI C, Zhang Y, Xia Q, Hao B, et al
    Multi-omics analysis revealed the mitochondrial-targeted drug combination to suppress the development of lung cancer.
    J Cancer Res Clin Oncol. 2023 Oct 2. doi: 10.1007/s00432-023-05376.
    PubMed     Abstract available
    
    
    
56. LIANG X, Guan R, Zhu J, Meng Y, et al
    A clinical decision support system to predict the efficacy for EGFR-TKIs based on artificial neural network.
    J Cancer Res Clin Oncol. 2023;149:12265-12274.
    PubMed     Abstract available
    
    
    
57. ZHANG JJ, Long ZB, Luo LL, Li LH, et al
    Feasibility analysis of rapid gene detection using intraoperative frozen tissues: comparison of intraoperative frozen tissues with paraffin-embedded tissues in epidermal growth factor receptor gene mutation detection of lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2023;149:12025-12032.
    PubMed     Abstract available
    
    
    
58. SHI J, Peng B, Zhou X, Wang C, et al
    An anoikis-based gene signature for predicting prognosis in malignant pleural mesothelioma and revealing immune infiltration.
    J Cancer Res Clin Oncol. 2023;149:12089-12102.
    PubMed     Abstract available
    
    
    
59. JIANG L, Tong Y, Jiang J, Zhao D, et al
    Two novel clinical tools to predict the risk of bone metastasis and overall survival in esophageal cancer patients: a large population-based retrospective cohort study.
    J Cancer Res Clin Oncol. 2023;149:11759-11777.
    PubMed     Abstract available
    
    
    
60. WEI Q, Jiang X, Miao X, Zhang Y, et al
    Molecular subtypes of lung adenocarcinoma patients for prognosis and therapeutic response prediction with machine learning on 13 programmed cell death patterns.
    J Cancer Res Clin Oncol. 2023;149:11351-11368.
    PubMed     Abstract available
    
    
    
61. XIAO Z, Zhang M, Liu Z, Wang X, et al
    Distance between tumor and bronchial resection margin is an independent predictor of recurrence-free survival and overall survival in primary endobronchial neoplasm.
    J Cancer Res Clin Oncol. 2023;149:11171-11180.
    PubMed     Abstract available
    
    
    
62. GOFRIT ON, Gofrit B, Roditi Y, Popovtzer A, et al
    The different clonal origins of metachronous and synchronous metastases.
    J Cancer Res Clin Oncol. 2023;149:11085-11092.
    PubMed     Abstract available
    
    
    
63. CHEN X, Li Z, Wang X, Zhou J, et al
    Investigation and verification of GIMAP6 as a robust biomarker for prognosis and tumor immunity in lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2023;149:11041-11055.
    PubMed     Abstract available
    
    
    September 2023
64. BRATOVA M, Skrickova J, Matusikova M, Hrabcova K, et al
    Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2023 Sep 28. doi: 10.1007/s00432-023-05431.
    PubMed     Abstract available
    
    
    
65. WU R, Zhang B, He M, Kang Y, et al
    MicroRNA biomarkers and their use in evaluating the prognosis of lung cancer.
    J Cancer Res Clin Oncol. 2023 Sep 20. doi: 10.1007/s00432-023-05404.
    PubMed     Abstract available
    
    
    
66. ZHAO K, Xia C, Qiu M, Yang Z, et al
    Lobar or sublobar resection for early-stage second primary lung cancer
    J Cancer Res Clin Oncol. 2023 Sep 19. doi: 10.1007/s00432-023-05396.
    PubMed     Abstract available
    
    
    
67. HUANG F, Cui J, Wan J, Yuan X, et al
    SLC12A8 mediates TKI resistance in EGFR-mutant lung cancer via PDK1/AKT axis.
    J Cancer Res Clin Oncol. 2023 Sep 19. doi: 10.1007/s00432-023-05416.
    PubMed     Abstract available
    
    
    
68. ZHANG Y, Xu H, Pi S, Tan H, et al
    The prognostic and immunological role of FKBP1A in an integrated muti-omics cancers analysis, especially lung cancer.
    J Cancer Res Clin Oncol. 2023 Sep 16. doi: 10.1007/s00432-023-05362.
    PubMed     Abstract available
    
    
    
69. VOORN MJJ, Bastiaansen EMW, Schroder CD, van Kampen-van den Boogaart VEM, et al
    A qualitative stakeholder analysis of beliefs, facilitators, and barriers for a feasible prehabilitation program before lung cancer surgery.
    J Cancer Res Clin Oncol. 2023 Sep 5. doi: 10.1007/s00432-023-05298.
    PubMed     Abstract available
    
    
    
70. XIONG L, Zhu C, Lu Y, Chen M, et al
    Serum THBS2 is a potential biomarker for the diagnosis of non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2023 Sep 2. doi: 10.1007/s00432-023-05330.
    PubMed     Abstract available
    
    
    
71. WALIA A, Prasad V
    Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC.
    J Cancer Res Clin Oncol. 2023;149:9513-9515.
    PubMed     Abstract available
    
    
    
72. GE X, Xu H, Weng S, Zhang Y, et al
    Systematic analysis of transcriptome signature for improving outcomes in lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2023;149:8951-8968.
    PubMed     Abstract available
    
    
    
73. LIN Y, Yu B, Sun H, Zhang H, et al
    Promising efficacy of immune checkpoint inhibitor plus chemotherapy for thoracic SMARCA4-deficient undifferentiated tumor.
    J Cancer Res Clin Oncol. 2023;149:8663-8671.
    PubMed     Abstract available
    
    
    
74. KANDEMIR EA, Karaomerlioglu I, Yaradilmis IM
    Off-label use of immune checkpoint inhibitors for the treatment of solid tumors: analysis of a nationwide patient sample.
    J Cancer Res Clin Oncol. 2023;149:8655-8662.
    PubMed     Abstract available
    
    
    
75. WANG Y, Luo F, Yang X, Wang Q, et al
    The Swin-Transformer network based on focal loss is used to identify images of pathological subtypes of lung adenocarcinoma with high similarity and class imbalance.
    J Cancer Res Clin Oncol. 2023;149:8581-8592.
    PubMed     Abstract available
    
    
    
76. JI XY, Li H, Chen HH, Lin J, et al
    Diagnostic performance of RASSF1A and SHOX2 methylation combined with EGFR mutations for differentiation between small pulmonary nodules.
    J Cancer Res Clin Oncol. 2023;149:8557-8571.
    PubMed     Abstract available
    
    
    
77. FUJIKI H, Sueoka E, Watanabe T, Komori A, et al
    Cancer progression by the okadaic acid class of tumor promoters and endogenous protein inhibitors of PP2A, SET and CIP2A.
    J Cancer Res Clin Oncol. 2023;149:9425-9433.
    PubMed     Abstract available
    
    
    
78. WEN R, Chen Y, Long J, Huang X, et al
    Aggressive progression to EGFR tyrosine kinase inhibitors in advanced NSCLC patients: concomitant mutations, prognostic indicator and subsequent management.
    J Cancer Res Clin Oncol. 2023;149:8307-8316.
    PubMed     Abstract available
    
    
    
79. YU XQ, Weber M, Smith D, Velentzis L, et al
    Incidence profile of four major cancers among migrants in Australia, 2005-2014.
    J Cancer Res Clin Oncol. 2023;149:8317-8325.
    PubMed     Abstract available
    
    
    
80. FRANZESE C, Vernier V, Franceschini D, Comito T, et al
    Total tumor volume as a predictor of survival in patients with multiple oligometastases treated with stereotactic ablative radiotherapy (SABR).
    J Cancer Res Clin Oncol. 2023;149:10495-10503.
    PubMed     Abstract available
    
    
    
81. SHEN R, Li Z, Wu X
    The mitotic spindle-related seven-gene predicts the prognosis and immune microenvironment of lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2023;149:10131-10141.
    PubMed     Abstract available
    
    
    
82. SAMUELS N, Cohen N, Katz D, Ben-Arye E, et al
    Identifying cultural, demographic, personal health and cancer-related barriers to integrative oncology care: a retrospective case-cohort study.
    J Cancer Res Clin Oncol. 2023;149:10143-10148.
    PubMed     Abstract available
    
    
    
83. LIAO Y, Chen Y, Liu S, Wang W, et al
    Low-dose total body irradiation enhances systemic anti-tumor immunity induced by local cryotherapy.
    J Cancer Res Clin Oncol. 2023;149:10053-10063.
    PubMed     Abstract available
    
    
    
84. FENG KP, Fu K, Xu C, Ding C, et al
    NSCLC patients with a changing T grade after operation may represent a special subset of tumor staging.
    J Cancer Res Clin Oncol. 2023;149:9991-9998.
    PubMed     Abstract available
    
    
    
85. HE Y, Xiong Z, Zhang J, Xie J, et al
    Growth assessment of pure ground-glass nodules on CT: comparison of density and size measurement methods.
    J Cancer Res Clin Oncol. 2023;149:9937-9946.
    PubMed     Abstract available
    
    
    
86. DONG H, Wang X, Qiu Y, Lou C, et al
    Establishment and visualization of a model based on high-resolution CT qualitative and quantitative features for prediction of micropapillary or solid components in invasive lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2023;149:10519-10530.
    PubMed     Abstract available
    
    
    
87. JIANG B, Hu L, Dong D, Guo Z, et al
    TP53 or CDKN2A/B covariation in ALK/RET/ROS1-rearranged NSCLC is associated with a high TMB, tumor immunosuppressive microenvironment and poor prognosis.
    J Cancer Res Clin Oncol. 2023;149:10041-10052.
    PubMed     Abstract available
    
    
    August 2023
88. BEDIR A, Mehrotra S, Gnuchtel J, Vordermark D, et al
    Treatment patterns in stage III non?small?cell lung cancer patients: a population?based study using German cancer registry data.
    J Cancer Res Clin Oncol. 2023 Aug 30. doi: 10.1007/s00432-023-05289.
    PubMed     Abstract available
    
    
    
89. LI L, Zhou X, Cui W, Li Y, et al
    Combining radiomics and deep learning features of intra-tumoral and peri-tumoral regions for the classification of breast cancer lung metastasis and primary lung cancer with low-dose CT.
    J Cancer Res Clin Oncol. 2023 Aug 29. doi: 10.1007/s00432-023-05329.
    PubMed     Abstract available
    
    
    
90. ZHANG Y, Chao F, Lv L, Li M, et al
    Hsa_circ_0041150 serves as a novel biomarker for monitoring chemotherapy resistance in small cell lung cancer patients treated with a first-line chemotherapy regimen.
    J Cancer Res Clin Oncol. 2023 Aug 28. doi: 10.1007/s00432-023-05317.
    PubMed     Abstract available
    
    
    
91. DOUBRE H, Greillier L, Justeau G, Ricordel C, et al
    Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 >/= 50% advanced non small cell lung cancer.
    J Cancer Res Clin Oncol. 2023 Aug 25. doi: 10.1007/s00432-023-05321.
    PubMed     Abstract available
    
    
    
92. RUAN M, Chang C, Sun J, Liu L, et al
    Exploring the correlation between HER2 alterations and (18)F-FDG PET/CT metabolic parameters and their prognostic value in EGFR-negative non-small-cell lung cancer patients.
    J Cancer Res Clin Oncol. 2023 Aug 12. doi: 10.1007/s00432-023-05218.
    PubMed     Abstract available
    
    
    
93. YANG T, Qiao S, Zhu X
    High-dose radiation-resistant lung cancer cells stored many functional lipid drops through JAK2/p-STAT3/FASN pathway.
    J Cancer Res Clin Oncol. 2023 Aug 9. doi: 10.1007/s00432-023-05106.
    PubMed     Abstract available
    
    
    
94. XIAO N, Cao X, Liu Z, Han Y, et al
    Two germline mutations can serve as genetic susceptibility screening makers for a lung adenocarcinoma family.
    J Cancer Res Clin Oncol. 2023;149:6541-6548.
    PubMed     Abstract available
    
    
    
95. MOKSUD N, Wagner M, Pawelczyk K, Porebska I, et al
    Common inherited variants of PDCD1, CD274 and HAVCR2 genes differentially modulate the risk and prognosis of adenocarcinoma and squamous cell carcinoma.
    J Cancer Res Clin Oncol. 2023;149:6381-6390.
    PubMed     Abstract available
    
    
    
96. CHEN M, Chen X, Zhang Y, Wang W, et al
    Clinical and molecular features of pulmonary NUT carcinoma characterizes diverse responses to immunotherapy, with a pathologic complete response case.
    J Cancer Res Clin Oncol. 2023;149:6361-6370.
    PubMed     Abstract available
    
    
    
97. SCHMIDT M, Mattern S, Singer S, Schulze M, et al
    NOTCH3 missense mutations as predictor of long-term response to gemcitabine in a patient with epithelioid hemangioendothelioma.
    J Cancer Res Clin Oncol. 2023;149:6753-6757.
    PubMed     Abstract available
    
    
    
98. ZHANG Z, Yin F, Kang S, Tuo X, et al
    Dual-layer spectral detector CT (SDCT) can improve the detection of mixed ground-glass lung nodules.
    J Cancer Res Clin Oncol. 2023;149:5901-5906.
    PubMed     Abstract available
    
    
    
99. QIU D, Xi H, Wang M, Jing P, et al
    The debatable role of immune checkpoint blockade therapy in lung adenocarcinoma-oriented liver metastatic malignant lesions.
    J Cancer Res Clin Oncol. 2023;149:5791-5802.
    PubMed     Abstract available
    
    
    
100. SCHRENK KG, Weschenfelder W, Spiegel C, Agaimy A, et al
     Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma.
     J Cancer Res Clin Oncol. 2023;149:5493-5496.
     PubMed     Abstract available
     
     
     
101. LI X, Liu Y, Zhou Y, Gao Y, et al
     Day surgery unit robotics thoracic surgery: feasibility and management.
     J Cancer Res Clin Oncol. 2023;149:7831-7836.
     PubMed     Abstract available
     
     
     
102. AKARSU M, Ak G, Dundar E, Metintas M, et al
     Genetic analysis of familial predisposition in the pathogenesis of malignant pleural mesothelioma.
     J Cancer Res Clin Oncol. 2023;149:7767-7778.
     PubMed     Abstract available
     
     
     
103. ZHAO ZR, Yu YH, Lin ZC, Ma DH, et al
     Invasiveness assessment by artificial intelligence against intraoperative frozen section for pulmonary nodules
     J Cancer Res Clin Oncol. 2023;149:7759-7765.
     PubMed     Abstract available
     
     
     
104. HE X, Su Y, Liu P, Chen C, et al
     Machine learning-based immune prognostic model and ceRNA network construction for lung adenocarcinoma.
     J Cancer Res Clin Oncol. 2023;149:7379-7392.
     PubMed     Abstract available
     
     
     
105. GURAV M, Epari S, Gogte P, Pai T, et al
     Targeted molecular profiling of solid tumours-Indian tertiary cancer centre experience.
     J Cancer Res Clin Oncol. 2023;149:7413-7425.
     PubMed     Abstract available
     
     
     
106. SUN J, Li F, Yang J, Lin C, et al
     Pretherapy investigations using highly robust visualized biomarkers from CT imaging by multiple machine-learning techniques toward its prognosis prediction for ALK-inhibitor therapy in NSCLC: a feasibility study.
     J Cancer Res Clin Oncol. 2023;149:7341-7353.
     PubMed     Abstract available
     
     
     
107. NIU Y, Han X, Zeng Y, Nanding A, et al
     The significance of spread through air spaces in the prognostic assessment model of stage I lung adenocarcinoma and the exploration of its invasion mechanism.
     J Cancer Res Clin Oncol. 2023;149:7125-7138.
     PubMed     Abstract available
     
     
     
108. ZHANG Q, Cai G, Cui F, Li F, et al
     The relationship of airflow limitation with lung squamous cell carcinoma: evidence from mendelian randomization analysis.
     J Cancer Res Clin Oncol. 2023;149:6999-7006.
     PubMed     Abstract available
     
     
     
109. ZHENG S, Ye T, Li B, Zhang Y, et al
     Bleeding-related re-exploration following pulmonary resection: a report of a single-center experience.
     J Cancer Res Clin Oncol. 2023;149:6841-6848.
     PubMed     Abstract available
     
     
     July 2023
110. KONG F, Wang N, Gao F, Liang Y, et al
     The clinical application of atorvastatin in patients with small-cell lung cancer with dyslipidemia.
     J Cancer Res Clin Oncol. 2023 Jul 31. doi: 10.1007/s00432-023-05102.
     PubMed     Abstract available
     
     
     
111. GUO J, Zhang L, Zhang L, Wu J, et al
     The additional radiotherapy to adjuvant chemotherapy improves the prognosis of stage III-N2 with highest mediastinal lymph node metastasis in non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2023 Jul 24. doi: 10.1007/s00432-023-05101.
     PubMed     Abstract available
     
     
     
112. TAKAMORI S, Shimokawa M, Komiya T
     Efficacy of immune checkpoint inhibitors in younger patients with non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2023 Jul 21. doi: 10.1007/s00432-023-05167.
     PubMed     Abstract available
     
     
     
113. QU A, Zhang S, Zou H, Li S, et al
     Outcome benefits of bevacizumab biosimilar (SIBP04) combined with carboplatin and paclitaxel in advanced non-squamous non-small-cell lung cancer patients with EGFR mutation: subgroup analysis of a prospective, randomized phase III clinical trial.
     J Cancer Res Clin Oncol. 2023 Jul 15. doi: 10.1007/s00432-023-05103.
     PubMed     Abstract available
     
     
     
114. POLANCO D, Pinilla L, Gracia-Lavedan E, Gatius S, et al
     Performance of endobronchial ultrasound transbronchial needle aspiration as the first nodal staging procedure for the determination of programmed death ligand-1 expression in non-small cell lung cancer patients.
     J Cancer Res Clin Oncol. 2023 Jul 14. doi: 10.1007/s00432-023-05039.
     PubMed     Abstract available
     
     
     
115. NAITO T, Minegishi Y, Shiraishi H, Hoshino T, et al
     Influence of background cardiovascular risk factors on VEGF inhibitor-related adverse vascular events in patients with non-small cell lung cancer: a retrospective study.
     J Cancer Res Clin Oncol. 2023 Jul 13. doi: 10.1007/s00432-023-05092.
     PubMed     Abstract available
     
     
     
116. SHI J, Peng B, Wang C, Zhou X, et al
     Development and validation of a nomogram for predicting overall survival of resected N2 non-small cell lung cancer patients undergoing neoadjuvant radiotherapy.
     J Cancer Res Clin Oncol. 2023 Jul 5. doi: 10.1007/s00432-023-05073.
     PubMed     Abstract available
     
     
     
117. WALTER J, Moeller C, Resuli B, Kauffmann-Guerrero D, et al
     Guideline adherence of tumor board recommendations in lung cancer and transfer into clinical practice.
     J Cancer Res Clin Oncol. 2023 Jul 5. doi: 10.1007/s00432-023-05025.
     PubMed     Abstract available
     
     
     
118. ZHANG Y, Liu X, Gu Y, Zhang S, et al
     Clinical, laboratory, pathological, and radiological characteristics and prognosis of patients with pulmonary salivary gland-type tumors.
     J Cancer Res Clin Oncol. 2023;149:4025-4039.
     PubMed     Abstract available
     
     
     
119. LI G, Yang M, Ran L, Jin F, et al
     Classification prediction of early pulmonary nodes based on weighted gene correlation network analysis and machine learning.
     J Cancer Res Clin Oncol. 2023;149:3915-3924.
     PubMed     Abstract available
     
     
     
120. WAHLI MN, Hayoz S, Hoch D, Ryser CO, et al
     The role of immune checkpoint inhibitors in clinical practice: an analysis of the treatment patterns, survival and toxicity rates by sex.
     J Cancer Res Clin Oncol. 2023;149:3847-3858.
     PubMed     Abstract available
     
     
     
121. QU R, Ye F, Hu S, Wang B, et al
     Distinct cellular immune profiles in lung adenocarcinoma manifesting as pure ground glass opacity versus solid nodules.
     J Cancer Res Clin Oncol. 2023;149:3775-3788.
     PubMed     Abstract available
     
     
     
122. AMORRORTU RP, Zhao Y, Stewart S, Ghia KM, et al
     History of keratinocyte carcinoma and survival after a second primary malignancy: the Moffitt Cancer Center patient experience.
     J Cancer Res Clin Oncol. 2023;149:3607-3621.
     PubMed     Abstract available
     
     
     
123. GUVEN DC, Yekeduz E, Erul E, Yazgan SC, et al
     The benefit of treatment beyond progression with immune checkpoint inhibitors: a multi-center retrospective cohort study.
     J Cancer Res Clin Oncol. 2023;149:3599-3606.
     PubMed     Abstract available
     
     
     
124. ZHANG Z, Li Z, Zhang X, Ye W, et al
     Association between secondhand smoke and cancers in adults in the US population.
     J Cancer Res Clin Oncol. 2023;149:3447-3455.
     PubMed     Abstract available
     
     
     
125. ZHAO W, Xiong Z, Jiang Y, Wang K, et al
     Radiomics based on enhanced CT for differentiating between pulmonary tuberculosis and pulmonary adenocarcinoma presenting as solid nodules or masses.
     J Cancer Res Clin Oncol. 2023;149:3395-3408.
     PubMed     Abstract available
     
     
     
126. FLORSCH B, Taugner J, Kasmann L, Kenndoff S, et al
     Treatment patterns and prognosis of patients with inoperable stage III NSCLC after completion of concurrent chemoradiotherapy +/- immune checkpoint inhibition: a decade-long single-center historical analysis.
     J Cancer Res Clin Oncol. 2023;149:3267-3276.
     PubMed     Abstract available
     
     
     
127. WANG N, Zhu Y, Wu Y, Huang B, et al
     MET overexpression in EGFR L858R mutant treatment-naive advanced lung adenocarcinoma correlated with poor prognosis: a real-world retrospective study.
     J Cancer Res Clin Oncol. 2023;149:3219-3228.
     PubMed     Abstract available
     
     
     
128. HU F, Peng J, Mao X, Niu Y, et al
     Prognosis of different extrathoracic metastasis patterns in patients with M1c lung adenocarcinoma receiving immunotherapy.
     J Cancer Res Clin Oncol. 2023;149:3171-3184.
     PubMed     Abstract available
     
     
     
129. LU C, Wei XW, Zhang YC, Chen ZH, et al
     Selective RET inhibitors shift the treatment pattern of RET fusion-positive NSCLC and improve survival outcomes.
     J Cancer Res Clin Oncol. 2023;149:2987-2995.
     PubMed     Abstract available
     
     
     
130. LI P, Che S, Qi Y, Luo N, et al
     Age-dependent genomic characteristics and their impact on immunotherapy in lung adenocarcinoma.
     J Cancer Res Clin Oncol. 2023;149:2997-3007.
     PubMed     Abstract available
     
     
     
131. SUN S, Liu C, Duan C, Yu S, et al
     Efficacy and safety of immune checkpoint inhibitors in post-TKI NSCLC patients harboring EGFR mutations.
     J Cancer Res Clin Oncol. 2023;149:2937-2949.
     PubMed     Abstract available
     
     
     
132. THOMAS AR, Liu C, Tong YT, Tan D, et al
     Characteristics and outcomes of cancer patients with pre-existing microscopic colitis after exposure to PD-1 and PD-L1 inhibitors.
     J Cancer Res Clin Oncol. 2023;149:5429-5436.
     PubMed     Abstract available
     
     
     
133. WANG L, Chen Q, Liu T, Bai T, et al
     Role and mechanism of benzo[a]pyrene in the transformation of chronic obstructive pulmonary disease into lung adenocarcinoma.
     J Cancer Res Clin Oncol. 2023;149:4741-4760.
     PubMed     Abstract available
     
     
     
134. SHI Q, Zhang XX, Shi XQ, Chen Y, et al
     Identification of rs2736099 as a novel cis-regulatory variation for TERT and implications for tumorigenesis and cell proliferation.
     J Cancer Res Clin Oncol. 2023;149:4515-4522.
     PubMed     Abstract available
     
     
     June 2023
135. LI JD, Jin CY, Zhang Y, Guo H, et al
     Spontaneous histological transformation of lung squamous-cell carcinoma to large cell neuroendocrine carcinoma and small cell lung cancer.
     J Cancer Res Clin Oncol. 2023 Jun 28. doi: 10.1007/s00432-023-04990.
     PubMed     Abstract available
     
     
     
136. SIDDIQUI EA, Chaurasia V, Shandilya M
     Classification of lung cancer computed tomography images using a 3-dimensional deep convolutional neural network with multi-layer filter.
     J Cancer Res Clin Oncol. 2023 Jun 27. doi: 10.1007/s00432-023-04992.
     PubMed     Abstract available
     
     
     
137. LI Z, Pang M, Liang X, Zhang Y, et al
     Risk factors of early mortality in patients with small cell lung cancer: a retrospective study in the SEER database.
     J Cancer Res Clin Oncol. 2023 Jun 24. doi: 10.1007/s00432-023-05003.
     PubMed     Abstract available
     
     
     
138. TANG S, Xu L, Wu Z, Wen Q, et al
     A novel immunogenomic classification for prognosis in non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2023 Jun 17. doi: 10.1007/s00432-023-04887.
     PubMed     Abstract available
     
     
     
139. ZHOU Q, Zhang HL, Jiang LY, Shi YK, et al
     Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS study.
     J Cancer Res Clin Oncol. 2023 Jun 14. doi: 10.1007/s00432-023-04923.
     PubMed     Abstract available
     
     
     
140. LIAO YT, Wang LC, Sun RL, Yeh YC, et al
     Characteristics, treatment patterns, and clinical outcomes in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions.
     J Cancer Res Clin Oncol. 2023 Jun 5. doi: 10.1007/s00432-023-04921.
     PubMed     Abstract available
     
     
     
141. LUO J, Mei Z, Lin S, Xing X, et al
     Integrative pan-cancer analysis reveals the importance of PAQR family in lung cancer.
     J Cancer Res Clin Oncol. 2023 Jun 2. doi: 10.1007/s00432-023-04922.
     PubMed     Abstract available
     
     
     
142. ARMSTRONG S, Roy T, Singh B, Kulasekaran M, et al
     TKIs beyond immunotherapy predict improved survival in advanced HCC.
     J Cancer Res Clin Oncol. 2023;149:2559-2574.
     PubMed     Abstract available
     
     
     
143. AWIDI M, Connell B, Johnson D, Craven I, et al
     Safety of sequential immune checkpoint inhibitors after prior immune therapy.
     J Cancer Res Clin Oncol. 2023;149:2375-2382.
     PubMed     Abstract available
     
     
     
144. CAI R, Zhu H, Liu Y, Sha H, et al
     To be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations.
     J Cancer Res Clin Oncol. 2023 Jun 1. doi: 10.1007/s00432-023-04919.
     PubMed     Abstract available
     
     
     May 2023
145. JIN E
     Flexible nursing in patients with lung cancer who received chemotherapy.
     J Cancer Res Clin Oncol. 2023 May 31. doi: 10.1007/s00432-023-04876.
     PubMed     Abstract available
     
     
     
146. MU D, Tang H, Teng G, Li X, et al
     Differences of genomic alterations and heavy metals in non-small cell lung cancer with different histological subtypes.
     J Cancer Res Clin Oncol. 2023 May 31. doi: 10.1007/s00432-023-04929.
     PubMed     Abstract available
     
     
     
147. PAN H, Zhang J, Tian Y, Zou N, et al
     Short- and long-term outcomes of robotic-assisted versus video-assisted thoracoscopic lobectomy in non-small cell lung cancer patients aged 35 years or younger: a real-world study with propensity score-matched analysis.
     J Cancer Res Clin Oncol. 2023 May 30. doi: 10.1007/s00432-023-04933.
     PubMed     Abstract available
     
     
     
148. ALBAYRAK A, Duzenli T, Kayikcioglu E
     Potential drug-drug interactions in patients with non-small cell lung cancer at a university hospital in Turkey.
     J Cancer Res Clin Oncol. 2023 May 24. doi: 10.1007/s00432-023-04890.
     PubMed     Abstract available
     
     
     
149. GUO J, Ding W, Cai S, Ren P, et al
     Polydatin radiosensitizes lung cancer while preventing radiation injuries by modulating tumor-infiltrating B cells.
     J Cancer Res Clin Oncol. 2023 May 23. doi: 10.1007/s00432-023-04762.
     PubMed     Abstract available
     
     
     
150. SUN H, Zhou P, Chen G, Dai Z, et al
     Radiomics nomogram for the prediction of Ki-67 index in advanced non-small cell lung cancer based on dual-phase enhanced computed tomography.
     J Cancer Res Clin Oncol. 2023 May 19. doi: 10.1007/s00432-023-04856.
     PubMed     Abstract available
     
     
     
151. KRASKOWSKI O, Stratmann JA, Wiesweg M, Eberhardt W, et al
     Favorable survival outcomes in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer sequentially treated with a tyrosine kinase inhibitor and osimertinib in a real-world setting.
     J Cancer Res Clin Oncol. 2023 May 18. doi: 10.1007/s00432-023-04839.
     PubMed     Abstract available
     
     
     
152. BIN Y, Ding P, Liu L, Tong F, et al
     Classification of the immune microenvironment associated with 12 cell death modes and construction of a prognostic model for squamous cell lung cancer.
     J Cancer Res Clin Oncol. 2023 May 12. doi: 10.1007/s00432-023-04789.
     PubMed     Abstract available
     
     
     
153. GAO J, Zhang P, Tang M, Nie X, et al
     Predictors of immune checkpoint inhibitor-related adverse events in older patients with lung cancer: a prospective real-world analysis.
     J Cancer Res Clin Oncol. 2023 May 10. doi: 10.1007/s00432-023-04792.
     PubMed     Abstract available
     
     
     
154. NIU L, Chu X, Yang X, Zhao H, et al
     A multiomics approach-based prediction of radiation pneumonia in lung cancer patients: impact on survival outcome.
     J Cancer Res Clin Oncol. 2023 May 8. doi: 10.1007/s00432-023-04827.
     PubMed     Abstract available
     
     
     
155. FAN X, Huang J, Hu B, Zhou J, et al
     Tumor-expressed B7-H3 promotes vasculogenic mimicry formation rather than angiogenesis in non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2023 May 2. doi: 10.1007/s00432-023-04790.
     PubMed     Abstract available
     
     
     
156. VAN TILBURG L, van de Ven SEM, Spaander MCW, van Kleef LA, et al
     Prevalence of lung tumors in patients with esophageal squamous cell carcinoma and vice versa: a systematic review and meta-analysis.
     J Cancer Res Clin Oncol. 2023;149:1811-1823.
     PubMed     Abstract available
     
     
     
157. WANG Y, Luo N, Gao Y, Wu Y, et al
     The joint detection of CEA and ctDNA in cerebrospinal fluid: an auxiliary tool for the diagnosis of leptomeningeal metastases in cancer.
     J Cancer Res Clin Oncol. 2023;149:1679-1690.
     PubMed     Abstract available
     
     
     April 2023
158. QI A, Jiao L, Zhang Y, Zhou H, et al
     Irritability and risk of lung cancer: a Mendelian randomization and mediation analysis.
     J Cancer Res Clin Oncol. 2023 Apr 27. doi: 10.1007/s00432-023-04791.
     PubMed     Abstract available
     
     
     
159. XI Y, Bai Z, Gao S, Guo J, et al
     Genomic profiling of NGS-based ctDNA from Chinese non-small cell lung cancer patients.
     J Cancer Res Clin Oncol. 2023 Apr 25. doi: 10.1007/s00432-023-04794.
     PubMed     Abstract available
     
     
     
160. WANG CX, Yan J, Lin S, Ding Y, et al
     Mutant-allele dispersion correlates with prognosis risk in patients with advanced non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2023 Apr 24. doi: 10.1007/s00432-023-04801.
     PubMed     Abstract available
     
     
     
161. ZHU M, Zhang J, Yang M, Zhang H, et al
     In vitro and in vivo study on the treatment of non-small cell lung cancer with radionuclide labeled PD-L1 nanobody.
     J Cancer Res Clin Oncol. 2023 Apr 21. doi: 10.1007/s00432-023-04793.
     PubMed     Abstract available
     
     
     
162. INAGAKI M, Uchiyama M, Yoshikawa-Kawabe K, Ito M, et al
     Comprehensive circulating microRNA profile as a supersensitive biomarker for early-stage lung cancer screening.
     J Cancer Res Clin Oncol. 2023 Apr 19:1-9. doi: 10.1007/s00432-023-04728.
     PubMed     Abstract available
     
     
     
163. SUN D, Hu J, Li X, He J, et al
     Real-world surgical treatment patterns and clinical outcomes in patients with stages IA-IIIA non-small cell lung cancer: a retrospective multicentric observational study involving 11,958 patients.
     J Cancer Res Clin Oncol. 2023 Apr 16. doi: 10.1007/s00432-023-04729.
     PubMed     Abstract available
     
     
     
164. MA H, Zhang Z, Hu Q, Chen H, et al
     Shedding light on macrophage immunotherapy in lung cancer.
     J Cancer Res Clin Oncol. 2023 Apr 13. doi: 10.1007/s00432-023-04740.
     PubMed     Abstract available
     
     
     
165. BAO Y, Yan E, Wang N
     Evaluation of GREM1 and THBS2 as prognostic markers in in non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2023 Apr 10. doi: 10.1007/s00432-023-04746.
     PubMed     Abstract available
     
     
     
166. ZHENG H, Nie D, Huang X
     Association between idiopathic pulmonary fibrosis and risk of different pathological types of lung cancer: a Mendelian randomization study.
     J Cancer Res Clin Oncol. 2023 Apr 3. doi: 10.1007/s00432-023-04727.
     PubMed     Abstract available
     
     
     
167. YAMAGUCHI A, Saito Y, Narumi K, Furugen A, et al
     Association between skin immune-related adverse events (irAEs) and multisystem irAEs during PD-1/PD-L1 inhibitor monotherapy.
     J Cancer Res Clin Oncol. 2023;149:1659-1666.
     PubMed     Abstract available
     
     
     
168. ULLAS B, Shrinidhi N, Mansi S, Narayan S, et al
     All EGFR mutations are (not) created equal: focus on uncommon EGFR mutations.
     J Cancer Res Clin Oncol. 2023;149:1541-1549.
     PubMed     Abstract available
     
     
     
169. BAI J, Deng C, Fu F, Li D, et al
     Pregnancy may have little influence on ground-glass opacities suspected for lung adenocarcinoma.
     J Cancer Res Clin Oncol. 2023;149:1383-1389.
     PubMed     Abstract available
     
     
     
170. SA H, Shi Y, Ding C, Ma K, et al
     A real-world study of the efficacy and safety of furmonertinib for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations.
     J Cancer Res Clin Oncol. 2023 Apr 1. doi: 10.1007/s00432-023-04726.
     PubMed     Abstract available
     
     
     March 2023
171. MAHGOUB EO, Abdella GM
     Improved exosome isolation methods from non-small lung cancer cells (NC1975) and their characterization using morphological and surface protein biomarker methods.
     J Cancer Res Clin Oncol. 2023 Mar 25. doi: 10.1007/s00432-023-04682.
     PubMed     Abstract available
     
     
     
172. KASMANN L, Eze C, Taugner J, Nieto A, et al
     Concurrent/sequential versus sequential immune checkpoint inhibition in inoperable large stage III non-small cell lung cancer patients treated with chemoradiotherapy: a prospective observational study.
     J Cancer Res Clin Oncol. 2023 Mar 20. doi: 10.1007/s00432-023-04654.
     PubMed     Abstract available
     
     
     
173. QIN H, Hu H, Liao X, Zhao P, et al
     Antitumor effect of neoantigen-reactive T cells combined with PD1 inhibitor therapy in mouse lung cancer.
     J Cancer Res Clin Oncol. 2023 Mar 18:1-16. doi: 10.1007/s00432-023-04683.
     PubMed     Abstract available
     
     
     
174. KIM JS, Kim EJ, Jang JG, Hong KS, et al
     Low diffusion capacity predicts poor prognosis in extensive stage small cell lung cancer: a single-center analysis of 10 years.
     J Cancer Res Clin Oncol. 2023 Mar 13. doi: 10.1007/s00432-023-04686.
     PubMed     Abstract available
     
     
     
175. TO KKW, Cheung KM, Cho WCS
     Repurposing of triamterene as a histone deacetylase inhibitor to overcome cisplatin resistance in lung cancer treatment.
     J Cancer Res Clin Oncol. 2023 Mar 11. doi: 10.1007/s00432-023-04641.
     PubMed     Abstract available
     
     
     
176. HONGWEI S, Xinzhong H, Huiqin X, Shuqin X, et al
     Standard deviation of CT radiomic features among malignancies in each individual: prognostic ability in lung cancer patients.
     J Cancer Res Clin Oncol. 2023 Mar 8. doi: 10.1007/s00432-023-04649.
     PubMed     Abstract available
     
     
     
177. SHI W, Ling L, Li C, Wu R, et al
     LncRNA UCA1 promoted cisplatin resistance in lung adenocarcinoma with HO1 targets NRF2/HO1 pathway.
     J Cancer Res Clin Oncol. 2023;149:1295-1311.
     PubMed     Abstract available
     
     
     
178. WEN W, Zhang Y, Zhang H, Chen Y, et al
     Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis.
     J Cancer Res Clin Oncol. 2023;149:969-978.
     PubMed     Abstract available
     
     
     
179. LI D, Tang L, Hu J, Cao X, et al
     Immune checkpoint inhibitors' combination therapy as first-line treatment in advanced esophageal squamous cell carcinoma: a meta-analysis.
     J Cancer Res Clin Oncol. 2023;149:933-939.
     PubMed     Abstract available
     
     
     
180. LIANG X, Zhang W, Li J, Zhu J, et al
     Clinical implications of ctDNA for EGFR-TKIs as first-line treatment in NSCLC.
     J Cancer Res Clin Oncol. 2023;149:1211-1220.
     PubMed     Abstract available
     
     
     
181. BAO H, Ma LZ, Zhao C, Yu M, et al
     Anti-angiogenic therapy for advanced primary pulmonary lymphoepithelioma-like carcinoma: a retrospective multicenter study.
     J Cancer Res Clin Oncol. 2023;149:1185-1193.
     PubMed     Abstract available
     
     
     
182. EHRET F, Kaul D, Kufeld M, Endt CV, et al
     Robotic stereotactic body radiotherapy for the management of adrenal gland metastases: a bi-institutional analysis.
     J Cancer Res Clin Oncol. 2023;149:1095-1101.
     PubMed     Abstract available
     
     
     
183. ZHANG S, Chen J, Zhang R, Xu L, et al
     Pulmonary neuroendocrine tumors: study of 266 cases focusing on clinicopathological characteristics, immunophenotype, and prognosis.
     J Cancer Res Clin Oncol. 2023;149:1063-1077.
     PubMed     Abstract available
     
     
     February 2023
184. LI C, Li J, Xiong S, Zhou H, et al
     Risk mapping of lung cancer: a comprehensive appraisal of published meta-analyses incorporating Mendelian randomization studies.
     J Cancer Res Clin Oncol. 2023 Feb 21. doi: 10.1007/s00432-023-04606.
     PubMed     Abstract available
     
     
     
185. YAO N, Pan J, Chen X, Li P, et al
     Discovery of potential biomarkers for lung cancer classification based on human proteome microarrays using Stochastic Gradient Boosting approach.
     J Cancer Res Clin Oncol. 2023 Feb 18. doi: 10.1007/s00432-023-04643.
     PubMed     Abstract available
     
     
     
186. MELLING N, Reeh M, Ghadban T, Tachezy M, et al
     RAI3 expression is not associated with clinical outcomes of patients with non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2023 Feb 13. doi: 10.1007/s00432-023-04631.
     PubMed     Abstract available
     
     
     
187. PATHAK N, Garg R, Khurana S, Kumar S, et al
     Improving the performance status in advanced non-small cell lung cancer patients with chemotherapy (ImPACt trial): a phase 2 study.
     J Cancer Res Clin Oncol. 2023 Feb 9. doi: 10.1007/s00432-023-04617.
     PubMed     Abstract available
     
     
     
188. ZHANG X, Gao H, Dang S, Dai L, et al
     Extracranial metastasis sites correlate to the incidence risk of brain metastasis in stage IV non-small cell lung cancer: a population-based study.
     J Cancer Res Clin Oncol. 2023 Feb 2. doi: 10.1007/s00432-022-04548.
     PubMed     Abstract available
     
     
     
189. SHAO F, Ling L, Li C, Huang X, et al
     Establishing a metastasis-related diagnosis and prognosis model for lung adenocarcinoma through CRISPR library and TCGA database.
     J Cancer Res Clin Oncol. 2023;149:885-899.
     PubMed     Abstract available
     
     
     
190. WU Z, Wang Y, Jin L, Wei J, et al
     Case report: identification of EGFR R776H and FANCE R381H germline mutations in a patient with multiple pulmonary nodules.
     J Cancer Res Clin Oncol. 2023;149:921-927.
     PubMed     Abstract available
     
     
     January 2023
191. GUGULOTHU VK, Balaji S
     An automatic classification of pulmonary nodules for lung cancer diagnosis using novel LLXcepNN classifier.
     J Cancer Res Clin Oncol. 2023 Jan 16. doi: 10.1007/s00432-022-04539.
     PubMed     Abstract available
     
     
     
192. LU S, Qin S, Zhou Z, Chen J, et al
     Bevacizumab biosimilar candidate TAB008 compared to Avastin((R)) in patients with locally advanced, metastatic EGFR wild-type non-squamous non-small cell lung cancer: a randomized, double-blind, multicenter study.
     J Cancer Res Clin Oncol. 2023 Jan 3. doi: 10.1007/s00432-022-04563.
     PubMed     Abstract available
     
     
     
193. UHLENBRUCH M, Kruger S
     Effect of antimicrobial therapy on progression-free survival of immunotherapy and chemo-/immunotherapy in patients with non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2023 Jan 3. doi: 10.1007/s00432-022-04567.
     PubMed     Abstract available
     
     
     
194. LI Q, Tang Y, Wang T, Zhu J, et al
     Novel immunogenic cell death-related risk signature to predict prognosis and immune microenvironment in lung adenocarcinoma.
     J Cancer Res Clin Oncol. 2023;149:307-323.
     PubMed     Abstract available
     
     
     
195. WANG M, Liu L, Dai Q, Jin M, et al
     Developing a primary tumor and lymph node 18F-FDG PET/CT-clinical (TLPC) model to predict lymph node metastasis of resectable T2-4 NSCLC.
     J Cancer Res Clin Oncol. 2023;149:247-261.
     PubMed     Abstract available
     
     
     December 2022
196. HONG G, Sun P, Chung C, Park D, et al
     Plasma GDF15 levels associated with circulating immune cells predict the efficacy of PD-1/PD-L1 inhibitor treatment and prognosis in patients with advanced non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2022 Dec 6. doi: 10.1007/s00432-022-04500.
     PubMed     Abstract available
     
     
     
197. ZHU Y, Zhang Y, Hu X, Wang M, et al
     PD-1 inhibitors plus chemotherapy in EGFR/ALK-positive NSCLC patients with brain metastases and disease progression after EGFR/ALK-TKIs therapy.
     J Cancer Res Clin Oncol. 2022;148:3557-3566.
     PubMed     Abstract available
     
     
     
198. NORITAKE O, Aokage K, Suzuki A, Tane K, et al
     Prognostic impact of the number of peri-tumoral alveolar macrophages in patients with stage I lung adenocarcinoma.
     J Cancer Res Clin Oncol. 2022;148:3437-3447.
     PubMed     Abstract available
     
     
     
199. XIAO Q, Koutsilieri S, Sismanoglou DC, Lauschke VM, et al
     CFTR reduces the proliferation of lung adenocarcinoma and is a strong predictor of survival in both smokers and non-smokers.
     J Cancer Res Clin Oncol. 2022;148:3293-3302.
     PubMed     Abstract available
     
     
     November 2022
200. HAN L, Huang Z, Zhang J, Chen Y, et al
     Significance of spread through air spaces in small cell lung cancer.
     J Cancer Res Clin Oncol. 2022 Nov 22. doi: 10.1007/s00432-022-04462.
     PubMed     Abstract available
     
     
     
201. WING SE, Jankowska MM, Zou X, Sosa E, et al
     Neighborhood disadvantage is associated with KRAS-mutated non-small cell lung cancer risk.
     J Cancer Res Clin Oncol. 2022 Nov 16. pii: 10.1007/s00432-022-04455.
     PubMed     Abstract available
     
     
     
202. CHEN J, Wang D, Chen H, Gu J, et al
     TMEM196 inhibits lung cancer metastasis by regulating the Wnt/beta-catenin signaling pathway.
     J Cancer Res Clin Oncol. 2022 Nov 10. pii: 10.1007/s00432-022-04363.
     PubMed     Abstract available
     
     
     
203. LIU K, Qin Z, Ge Y, Bian A, et al
     Acute kidney injury in advanced lung cancer patients treated with PD-1 inhibitors: a single center observational study.
     J Cancer Res Clin Oncol. 2022 Nov 3. pii: 10.1007/s00432-022-04437.
     PubMed     Abstract available
     
     
     
204. YU FY, Xu Q, Wei QY, Mo HY, et al
     ACC2 is under-expressed in lung adenocarcinoma and predicts poor clinical outcomes.
     J Cancer Res Clin Oncol. 2022;148:3145-3162.
     PubMed     Abstract available
     
     
     
205. CHIANG CL, Ho HL, Yeh YC, Lee CC, et al
     Prognosticators of osimertinib treatment outcomes in patients with EGFR-mutant non-small cell lung cancer and leptomeningeal metastasis.
     J Cancer Res Clin Oncol. 2022 Nov 1. pii: 10.1007/s00432-022-04396.
     PubMed     Abstract available
     
     
     October 2022
206. ANDO C, Ichihara E, Yokoyama T, Inoue K, et al
     More than one-third of advanced non-small-cell lung cancer patients do not receive immunochemotherapy due to intolerance.
     J Cancer Res Clin Oncol. 2022 Oct 29. pii: 10.1007/s00432-022-04415.
     PubMed     Abstract available
     
     
     
207. RAO W, Guo L, Ling Y, Dong L, et al
     Developing an effective quality evaluation strategy of next-generation sequencing for accurate detecting non-small cell lung cancer samples with variable characteristics: a real-world clinical practice.
     J Cancer Res Clin Oncol. 2022 Oct 28. pii: 10.1007/s00432-022-04388.
     PubMed     Abstract available
     
     
     
208. MA Z, Wang Z, Li Y, Zhang Y, et al
     Detection and treatment of lung adenocarcinoma at pre-/minimally invasive stage: is it lead-time bias?
     J Cancer Res Clin Oncol. 2022;148:2717-2722.
     PubMed     Abstract available
     
     
     
209. XIE J, Ruan Z, Zheng J, Gong Y, et al
     Detection of circulating rare cells benefitted the diagnosis of malignant solitary pulmonary nodules.
     J Cancer Res Clin Oncol. 2022;148:2681-2692.
     PubMed     Abstract available
     
     
     
210. WEI H, Zhou X, Yang H, Gong Y, et al
     Stereotactic body radiotherapy to the primary lung lesion improves the survival of the selected patients with non-oligometastatic NSCLC harboring EGFR activating mutation with first-line EGFR-TKIs: a real-world study.
     J Cancer Res Clin Oncol. 2022;148:2589-2598.
     PubMed     Abstract available
     
     
     September 2022
211. SHI S, Wu T, Ma Z, Zhang X, et al
     Serum-derived extracellular vesicles promote the growth and metastasis of non-small cell lung cancer by delivering the m6A methylation regulator HNRNPC through the regulation of DLGAP5.
     J Cancer Res Clin Oncol. 2022 Sep 29. pii: 10.1007/s00432-022-04375.
     PubMed     Abstract available
     
     
     
212. DENG HY, Qiu XM, Zhu DX, Tang XJ, et al
     The safety and feasibility of preoperative induction therapy of Savolitinib in non-small cell lung cancer patients with MET exon 14 skipping mutation.
     J Cancer Res Clin Oncol. 2022 Sep 28. pii: 10.1007/s00432-022-04370.
     PubMed     Abstract available
     
     
     
213. ZHANG R, Huo X, Wang Q, Zhang J, et al
     Prediction of TTF-1 expression in non-small-cell lung cancer using machine learning-based radiomics.
     J Cancer Res Clin Oncol. 2022 Sep 23. pii: 10.1007/s00432-022-04357.
     PubMed     Abstract available
     
     
     
214. KANG S, Jeong H, Park JE, Kim HS, et al
     Central nervous systemic efficacy of immune checkpoint inhibitors and concordance between intra/extracranial response in non-small cell lung cancer patients with brain metastasis.
     J Cancer Res Clin Oncol. 2022 Sep 22. pii: 10.1007/s00432-022-04251.
     PubMed     Abstract available
     
     
     
215. LI J, Liu M, Zhang X, Ji L, et al
     Plasma autoantibodies IgG and IgM to PD1/PDL1 as potential biomarkers and risk factors of lung cancer.
     J Cancer Res Clin Oncol. 2022 Sep 20. pii: 10.1007/s00432-022-04360.
     PubMed     Abstract available
     
     
     
216. HYUNG J, Yoon H, Choi CM, Yoon S, et al
     Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in patients with recurrent non-small cell lung cancer after definitive concurrent chemoradiation or radiotherapy.
     J Cancer Res Clin Oncol. 2022 Sep 5. pii: 10.1007/s00432-022-04287.
     PubMed     Abstract available
     
     
     
217. YANG Y, Xia Y, Su C, Chen J, et al
     Measuring the indirect cost associated with advanced non-small cell lung cancer: a nationwide cross-sectional study in China.
     J Cancer Res Clin Oncol. 2022 Sep 3. pii: 10.1007/s00432-022-04258.
     PubMed     Abstract available
     
     
     
218. XIE X, You M, Meng E, Wang S, et al
     Complete and durable response to crizotinib in a patient with malignant pleural mesothelioma harboring CD74-ROS1 fusion.
     J Cancer Res Clin Oncol. 2022;148:2561-2566.
     PubMed     Abstract available
     
     
     
219. HIZAL M, Bilgin B, Paksoy N, Atci MM, et al
     The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study).
     J Cancer Res Clin Oncol. 2022 Sep 1. pii: 10.1007/s00432-022-04252.
     PubMed     Abstract available
     
     
     
220. LAWI ZK, Al-Shuhaib MBS, Amara IB
     The rs1801280 SNP is associated with non-small cell lung carcinoma by exhibiting a highly deleterious effect on N-acetyltransferase 2.
     J Cancer Res Clin Oncol. 2022 Sep 1. pii: 10.1007/s00432-022-04332.
     PubMed     Abstract available
     
     
     August 2022
221. KANG HJ, Kwak YK, Kim M, Lee SJ, et al
     Application of real-time MRI-guided linear accelerator in stereotactic ablative body radiotherapy for non-small cell lung cancer: one step forward to precise targeting.
     J Cancer Res Clin Oncol. 2022 Aug 30. pii: 10.1007/s00432-022-04264.
     PubMed     Abstract available
     
     
     
222. WANG JL, Chen CS, Jia ZR, Miao LY, et al
     Efficacy and safety of EGFRTKIs plus Shenqi Fuzheng injection for non-small cell lung cancer patients with EGFR-sensitive mutations.
     J Cancer Res Clin Oncol. 2022 Aug 26. pii: 10.1007/s00432-022-04297.
     PubMed     Abstract available
     
     
     
223. MATSUZAWA R, Morise M, Kinoshita F, Tanaka I, et al
     Non-invasive early prediction of immune checkpoint inhibitor efficacy in non-small-cell lung cancer patients using on-treatment serum CRP and NLR.
     J Cancer Res Clin Oncol. 2022 Aug 25. pii: 10.1007/s00432-022-04300.
     PubMed     Abstract available
     
     
     
224. ZHANG L, Xie G, Xiao X, Cheng C, et al
     Characterization of PDL1 enhanced siRNA/albumin liposome for effective therapeutic function in lung cancer.
     J Cancer Res Clin Oncol. 2022 Aug 23. pii: 10.1007/s00432-022-04298.
     PubMed     Abstract available
     
     
     
225. HU P, Wan P, Xu A, Yan B, et al
     Neferine, a novel ROCK1-targeting inhibitor, blocks EMT process and induces apoptosis in non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2022 Aug 19. pii: 10.1007/s00432-022-04280.
     PubMed     Abstract available
     
     
     
226. WANKHEDE D, Hofman P, Grover S
     PD-1/PD-L1 inhibitors in treatment-naive, advanced non-small cell lung cancer patients with < 1% PD-L1 expression: a meta-analysis of randomized controlled trials.
     J Cancer Res Clin Oncol. 2022 Aug 19. pii: 10.1007/s00432-022-04286.
     PubMed     Abstract available
     
     
     
227. KIM JS, Kim S, Koh J, Kim M, et al
     Predictive role of galectin-3 for immune checkpoint blockades (ICBs) in advanced or metastatic non-small cell lung cancer: a potential new marker for ICB resistance.
     J Cancer Res Clin Oncol. 2022 Aug 17. pii: 10.1007/s00432-022-04275.
     PubMed     Abstract available
     
     
     
228. ZHANG Q, Qin S, Peng C, Liu Y, et al
     Circulating circular RNA hsa_circ_0023179 acts as a diagnostic biomarker for non-small-cell lung cancer detection.
     J Cancer Res Clin Oncol. 2022 Aug 16. pii: 10.1007/s00432-022-04254.
     PubMed     Abstract available
     
     
     
229. LIU Z, Gu X, Li Z, Shan S, et al
     Heterogeneous expression of ACE2, TMPRSS2, and FURIN at single-cell resolution in advanced non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2022 Aug 12. pii: 10.1007/s00432-022-04253.
     PubMed     Abstract available
     
     
     
230. LI B, Zhu T, Wu X, Chen S, et al
     The crosstalk between lung cancer cells and platelets promotes tumor angiogenesis in vivo and in vitro.
     J Cancer Res Clin Oncol. 2022 Aug 11. pii: 10.1007/s00432-022-04259.
     PubMed     Abstract available
     
     
     
231. ZHAO Y, Liu Y, Jia Y, Wang X, et al
     Fibroblast activation protein in the tumor microenvironment predicts outcomes of PD-1 blockade therapy in advanced non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2022 Aug 11. pii: 10.1007/s00432-022-04250.
     PubMed     Abstract available
     
     
     
232. KAPELERIS J, Muller Bark J, Ranjit S, Richard D, et al
     Modelling reoxygenation effects in non-small cell lung cancer cell lines and showing epithelial-mesenchymal transition.
     J Cancer Res Clin Oncol. 2022 Aug 6. pii: 10.1007/s00432-022-04242.
     PubMed     Abstract available
     
     
     
233. YAMADA Y, Shimada Y, Makino Y, Kudo Y, et al
     Clinical utility of psoas muscle volume in assessment of sarcopenia in patients with early-stage non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2022 Aug 2. pii: 10.1007/s00432-022-04234.
     PubMed     Abstract available
     
     
     
234. XIE X, Chen X, Luo N, Qi Y, et al
     Transformation of invasive lung adenocarcinoma with ALK rearrangement into pulmonary sarcomatoid carcinoma.
     J Cancer Res Clin Oncol. 2022;148:2165-2168.
     PubMed     Abstract available
     
     
     
235. LUO YH, Liu H, Wampfler JA, Tazelaar HD, et al
     Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation.
     J Cancer Res Clin Oncol. 2022;148:2099-2114.
     PubMed     Abstract available
     
     
     July 2022
236. LI S, Lu X, Zheng D, Chen W, et al
     Methyltransferase-like 3 facilitates lung cancer progression by accelerating m6A methylation-mediated primary miR-663 processing and impeding SOCS6 expression.
     J Cancer Res Clin Oncol. 2022 Jul 30. pii: 10.1007/s00432-022-04128.
     PubMed     Abstract available
     
     
     
237. FANG Y, Li Z, Chen H, Zhang T, et al
     Burden of lung cancer along with attributable risk factors in China from 1990 to 2019, and projections until 2030.
     J Cancer Res Clin Oncol. 2022 Jul 29. pii: 10.1007/s00432-022-04217.
     PubMed     Abstract available
     
     
     
238. HIGASHIYAMA RI, Horinouchi H, Kuchiba A, Matsumoto Y, et al
     Non-specific symptoms as a prodrome of immune-related adverse events in patients with non-small cell lung cancer receiving nivolumab: a consecutive analysis of 200 patients.
     J Cancer Res Clin Oncol. 2022 Jul 28. pii: 10.1007/s00432-022-04205.
     PubMed     Abstract available
     
     
     
239. ACHEAMPONG E, Morici M, Abed A, Bowyer S, et al
     Powering single-cell genomics to unravel circulating tumour cell subpopulations in non-small cell lung cancer patients.
     J Cancer Res Clin Oncol. 2022 Jul 28. pii: 10.1007/s00432-022-04202.
     PubMed     Abstract available
     
     
     
240. TAKEUCHI E, Kondo K, Okano Y, Kunishige M, et al
     Early mortality factors in immune checkpoint inhibitor monotherapy for advanced or metastatic non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2022 Jul 24. pii: 10.1007/s00432-022-04215.
     PubMed     Abstract available
     
     
     
241. INOUE Y, Inui N, Karayama M, Asada K, et al
     Serum immune modulators associated with immune-related toxicities and efficacy of atezolizumab in patients with non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2022 Jul 14. pii: 10.1007/s00432-022-04193.
     PubMed     Abstract available
     
     
     
242. KSIENSKI D, Gupta S, Truong PT, Bone J, et al
     Safety and efficacy of pembrolizumab for advanced nonsmall cell lung cancer: before and during the COVID-19 pandemic.
     J Cancer Res Clin Oncol. 2022 Jul 14. pii: 10.1007/s00432-022-04181.
     PubMed     Abstract available
     
     
     
243. ZHUO X, Guo H, Ma J, Lai J, et al
     Clinical characteristics and prognostic factors of patients with non-small cell lung cancer having HER2 alterations.
     J Cancer Res Clin Oncol. 2022 Jul 13. pii: 10.1007/s00432-022-04196.
     PubMed     Abstract available
     
     
     
244. KOWALSKI B, Valaperti A, Bezel P, Steiner UC, et al
     Analysis of cytokines in serum and bronchoalveolar lavage fluid in patients with immune-checkpoint inhibitor-associated pneumonitis: a cross-sectional case-control study.
     J Cancer Res Clin Oncol. 2022;148:1711-1720.
     PubMed     Abstract available
     
     
     June 2022
245. DE GIGLIO A, Deiana C, Di Federico A
     Bone-specific response according to MDA criteria predicts immunotherapy efficacy among advanced non-small cell lung cancer (NSCLC) patients.
     J Cancer Res Clin Oncol. 2022 Jun 24. pii: 10.1007/s00432-022-04120.
     PubMed     Abstract available
     
     
     
246. CHANG J, Jing X, Hua Y, Geng K, et al
     Programmed cell death 1 pathway inhibitors improve the overall survival of small cell lung cancer patients with brain metastases.
     J Cancer Res Clin Oncol. 2022 Jun 23. pii: 10.1007/s00432-022-04121.
     PubMed     Abstract available
     
     
     
247. HATA T, Sakaguchi C, Hirano K, Kobe H, et al
     Efficacy and safety of immuno-chemotherapy in patients with advanced non-small-cell lung cancer harboring oncogenic mutations: a multicenter retrospective study.
     J Cancer Res Clin Oncol. 2022 Jun 23. pii: 10.1007/s00432-022-04125.
     PubMed     Abstract available
     
     
     
248. CAI JS, Lin QY, Dou XM
     Is adjacent lobe invasion an T category upgrade factor for resected non-small cell lung cancer
     J Cancer Res Clin Oncol. 2022 Jun 21. pii: 10.1007/s00432-022-04102.
     PubMed     Abstract available
     
     
     
249. DURSLEWICZ J, Klimaszewska-Wisniewska A, Jozwicki J, Antosik P, et al
     Prognostic significance of MATR3 in stage I and II non-small cell lung cancer patients.
     J Cancer Res Clin Oncol. 2022 Jun 20. pii: 10.1007/s00432-022-04097.
     PubMed     Abstract available
     
     
     
250. WANG Y, Zhang J, Hu B, Wang J, et al
     Influencing factors of lung cancer patients' participation in shared decision-making: a cross-sectional study.
     J Cancer Res Clin Oncol. 2022 Jun 18. pii: 10.1007/s00432-022-04105.
     PubMed     Abstract available
     
     
     
251. GOMPELMANN D, Sinn K, Brugger J, Bernitzky D, et al
     Correlation of PD-L1 expression on tumour cells between diagnostic biopsies and surgical specimens of lung cancer in real life with respect to biopsy techniques and neoadjuvant treatment.
     J Cancer Res Clin Oncol. 2022 Jun 16. pii: 10.1007/s00432-022-04080.
     PubMed     Abstract available
     
     
     
252. BODOR JN, Bauman JR, Handorf EA, Ross EA, et al
     Real-world progression-free survival (rwPFS) and the impact of PD-L1 and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapy.
     J Cancer Res Clin Oncol. 2022 Jun 16. pii: 10.1007/s00432-022-04089.
     PubMed     Abstract available
     
     
     
253. GURBUZ M, Kutlu Y, Akkus E, Koksoy EB, et al
     Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group.
     J Cancer Res Clin Oncol. 2022 Jun 11. pii: 10.1007/s00432-022-04087.
     PubMed     Abstract available
     
     
     
254. LIU C, Hu C, Chen T, Jiang Y, et al
     The role of plasma exosomal lnc-SNAPC5-3:4 in monitoring the efficacy of anlotinib in the treatment of advanced non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2022 Jun 7. pii: 10.1007/s00432-022-04071.
     PubMed     Abstract available
     
     
     
255. CANAO F, Ferreira H, Neves NM
     Liposomal formulations for lung cancer treatment in the last two decades: a systematic review.
     J Cancer Res Clin Oncol. 2022 Jun 4. pii: 10.1007/s00432-022-04079.
     PubMed     Abstract available
     
     
     
256. ARNOLD S, Kortland J, Maltseva DV, Nersisyan SA, et al
     Fra-2 overexpression upregulates pro-metastatic cell-adhesion molecules, promotes pulmonary metastasis, and reduces survival in a spontaneous xenograft model of human breast cancer.
     J Cancer Res Clin Oncol. 2022;148:1525-1542.
     PubMed     Abstract available
     
     
     
257. WEN Z, Zhang Y, Fu F, Ma Z, et al
     Clinical, pathological and radiologic features of minute pulmonary meningothelial-like nodules.
     J Cancer Res Clin Oncol. 2022;148:1473-1479.
     PubMed     Abstract available
     
     
     
258. ITO M, Miyata Y, Hirano S, Irisuna F, et al
     Sensitivity and optimal clinicopathological features for mutation-targeted liquid biopsy in pN0M0 EGFR-mutant lung adenocarcinoma.
     J Cancer Res Clin Oncol. 2022;148:1419-1428.
     PubMed     Abstract available
     
     
     May 2022
259. CHENG ES, Weber MF, Steinberg J, Canfell K, et al
     Evaluating risk factors for lung cancer among never-smoking individuals using two Australian studies.
     J Cancer Res Clin Oncol. 2022 May 27. pii: 10.1007/s00432-022-04043.
     PubMed     Abstract available
     
     
     
260. RICCETTI N, Blettner M, Taylor K, Wehler B, et al
     Quality of life in lung cancer survivors treated with tyrosine-kinase inhibitors (TKI): results from the multi-centre cross-sectional German study LARIS.
     J Cancer Res Clin Oncol. 2022 May 24. pii: 10.1007/s00432-022-03975.
     PubMed     Abstract available
     
     
     
261. LIU X, Ma C, Liu H, Sun Z, et al
     M6A regulator expression patterns predict the immune microenvironment and prognosis of non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2022 May 20. pii: 10.1007/s00432-022-04032.
     PubMed     Abstract available
     
     
     
262. FAN Y, Sun R, Wang Z, Zhang Y, et al
     Detection of MET amplification by droplet digital PCR in peripheral blood samples of non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2022 May 18. pii: 10.1007/s00432-022-04048.
     PubMed     Abstract available
     
     
     
263. SONG J, Bai L, Zhai J, Xin Z, et al
     Allele frequency and proportion defined by circulating tumor DNA profiling predict tyrosine kinase inhibitors' therapeutic outcomes for non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2022 May 17. pii: 10.1007/s00432-022-03992.
     PubMed     Abstract available
     
     
     
264. ENGLMEIER F, Bleckmann A, Bruckl W, Griesinger F, et al
     Clinical benefit and cost-effectiveness analysis of liquid biopsy application in patients with advanced non-small cell lung cancer (NSCLC): a modelling approach.
     J Cancer Res Clin Oncol. 2022 May 9. pii: 10.1007/s00432-022-04034.
     PubMed     Abstract available
     
     
     
265. HAN C, Ding X, Li M, Luo N, et al
     Afatinib, an effective treatment for patient with lung squamous cell carcinoma harboring uncommon EGFR G719A and R776C co-mutations.
     J Cancer Res Clin Oncol. 2022;148:1265-1268.
     PubMed     Abstract available
     
     
     
266. LI T, Fang J, Chu J, Liu X, et al
     In vivo and in vitro inhibition of SCLC by combining dual cancer-specific recombinant adenovirus with Etoposide.
     J Cancer Res Clin Oncol. 2022;148:1073-1085.
     PubMed     Abstract available
     
     
     
267. ZHANG Y, Men Y, Wang J, Xing P, et al
     Epithelial circulating tumor cells with a heterogeneous phenotype are associated with metastasis in NSCLC.
     J Cancer Res Clin Oncol. 2022;148:1137-1146.
     PubMed     Abstract available
     
     
     
268. URAMOTO H, Takiguchi T, Koizumi T, Tanimoto A, et al
     Multi-institutional survey of malignant pleural mesothelioma patients in the Hokushin region.
     J Cancer Res Clin Oncol. 2022;148:1153-1158.
     PubMed     Abstract available
     
     
     April 2022
269. HAN X, Guo J, Tang X, Zhu H, et al
     Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer: a prospective, single-arm, phase II study in China.
     J Cancer Res Clin Oncol. 2022 Apr 28. pii: 10.1007/s00432-022-04023.
     PubMed     Abstract available
     
     
     
270. SHEN Y, Lu J, Hu F, Qian J, et al
     Effect and outcomes analysis of anlotinib in non-small cell lung cancer patients with liver metastasis: results from the ALTER 0303 phase 3 randomized clinical trial.
     J Cancer Res Clin Oncol. 2022 Apr 28. pii: 10.1007/s00432-022-03964.
     PubMed     Abstract available
     
     
     
271. TANG X, Huang H, Du P, Wang L, et al
     Intratumoral and peritumoral CT-based radiomics strategy reveals distinct subtypes of non-small-cell lung cancer.
     J Cancer Res Clin Oncol. 2022 Apr 17. pii: 10.1007/s00432-022-04015.
     PubMed     Abstract available
     
     
     
272. SHIJUBOU N, Sumi T, Yamada Y, Nakata H, et al
     Immunological and nutritional predictive factors in patients receiving pembrolizumab for the first-line treatment of non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2022 Apr 9. pii: 10.1007/s00432-022-03941.
     PubMed     Abstract available
     
     
     
273. KUDO K, Nishii K, Makimoto G, Ishikawa N, et al
     First and repeat rebiopsy for detecting EGFR T790M mutation in non-small-cell lung cancer: CS-Lung-003 prospective observational registry study.
     J Cancer Res Clin Oncol. 2022 Apr 6. pii: 10.1007/s00432-021-03893.
     PubMed     Abstract available
     
     
     
274. GURSOY P, Tatli AM, Erdem D, Goker E, et al
     Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study.
     J Cancer Res Clin Oncol. 2022 Apr 5. pii: 10.1007/s00432-022-03984.
     PubMed     Abstract available
     
     
     
275. XU X, Wang H, Yu Z, Chen X, et al
     A novel RET fusion in non-small cell lung cancer identified by next-generation sequencing: a case report.
     J Cancer Res Clin Oncol. 2022 Apr 2. pii: 10.1007/s00432-022-03969.
     PubMed     Abstract available
     
     
     
276. CHEN J, Yu Z, Li X, Xu G, et al
     A novel 3' truncated ALK cause ALK + in a patient with minimally invasive adenocarcinoma.
     J Cancer Res Clin Oncol. 2022;148:1005-1006.
     PubMed    
     
     
     March 2022
277. DU W, Chen C, Luo LF, He LN, et al
     Optimizing the tumor shrinkage threshold for evaluating immunotherapy efficacy for advanced non-small-cell lung cancer.
     J Cancer Res Clin Oncol. 2022 Mar 18. pii: 10.1007/s00432-022-03978.
     PubMed     Abstract available
     
     
     
278. ZHANG H, Liu M, Du G, Yu B, et al
     Immune checkpoints related-LncRNAs can identify different subtypes of lung cancer and predict immunotherapy and prognosis.
     J Cancer Res Clin Oncol. 2022 Mar 17. pii: 10.1007/s00432-022-03940.
     PubMed     Abstract available
     
     
     
279. PURDE MT, Niederer R, Wagner NB, Diem S, et al
     Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.
     J Cancer Res Clin Oncol. 2022;148:647-656.
     PubMed     Abstract available
     
     
     
280. YAN Y, Gao Z, Han H, Zhao Y, et al
     NRAS expression is associated with prognosis and tumor immune microenvironment in lung adenocarcinoma.
     J Cancer Res Clin Oncol. 2022;148:565-575.
     PubMed     Abstract available
     
     
     February 2022
281. WU G, Guo L, Gu Y, Huang T, et al
     The genomic characteristics of RET fusion positive tumors in Chinese non-small cell lung cancer (NSCLC) patients.
     J Cancer Res Clin Oncol. 2022 Feb 26. pii: 10.1007/s00432-022-03959.
     PubMed     Abstract available
     
     
     
282. ZHAO Q, Tong J, Liu X, Li S, et al
     Reversing resistance to immune checkpoint inhibitor by adding recombinant human adenovirus type 5 in a patient with small cell lung cancer with promoted immune infiltration: a case report.
     J Cancer Res Clin Oncol. 2022 Feb 25. pii: 10.1007/s00432-022-03931.
     PubMed     Abstract available
     
     
     
283. SUN C, Liu Y, Zhang P, Wang X, et al
     Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
     J Cancer Res Clin Oncol. 2022 Feb 22. pii: 10.1007/s00432-021-03896.
     PubMed     Abstract available
     
     
     
284. LIN X, Deng H, Li S, Xie X, et al
     Sintilimab with chemotherapy as first-line treatment for locally advanced or metastatic squamous non-small-cell lung cancer: a real-world data study.
     J Cancer Res Clin Oncol. 2022 Feb 10. pii: 10.1007/s00432-021-03903.
     PubMed     Abstract available
     
     
     
285. HE C, Wei C, Wen J, Chen S, et al
     Comprehensive analysis of NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases of NSCLC patients.
     J Cancer Res Clin Oncol. 2022;148:321-330.
     PubMed     Abstract available
     
     
     January 2022
286. NIEDER C, Aanes SG, Haukland E
     Primary systemic therapy for patients with brain metastases from lung cancer ineligible for targeted agents.
     J Cancer Res Clin Oncol. 2022 Jan 12. pii: 10.1007/s00432-022-03919.
     PubMed     Abstract available
     
     
     
287. CHEN Y, Jin Y, Hu X, Chen M, et al
     Infiltrating T lymphocytes in the tumor microenvironment of small cell lung cancer: a state of knowledge review.
     J Cancer Res Clin Oncol. 2022 Jan 8. pii: 10.1007/s00432-021-03895.
     PubMed     Abstract available
     
     
     
288. YU TT, Peng XC, Wang MF, Han N, et al
     Harnessing chlorin e6 loaded by functionalized iron oxide nanoparticles linked with glucose for target photodynamic therapy and improving of the immunogenicity of lung cancer.
     J Cancer Res Clin Oncol. 2022 Jan 8. pii: 10.1007/s00432-021-03879.
     PubMed     Abstract available
     
     
     
289. XU Z, Hao X, Yang K, Wang Q, et al
     Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort study.
     J Cancer Res Clin Oncol. 2022 Jan 4. pii: 10.1007/s00432-021-03901.
     PubMed     Abstract available
     
     
     
290. XU B, Cheng H, Li K, Lv Y, et al
     Carboplatin and nab-paclitaxel chemotherapy with or without atezolizumab as front-line management for treatment-naive metastatic nonsquamous non-small cell lung cancer with PD-L1 staining: a retrospective study.
     J Cancer Res Clin Oncol. 2022 Jan 1. pii: 10.1007/s00432-021-03873.
     PubMed     Abstract available
     
     
     December 2021
291. WANG P, Yin T, Zhao K, Yu J, et al
     Correction to: Efficacy of single-site radiotherapy plus PD-1 inhibitors vs PD-1 inhibitors for oligometastatic non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2021 Dec 8. pii: 10.1007/s00432-021-03877.
     PubMed    
     
     
     
292. WEBER D, Decker M, Schuster M, Folz S, et al
     Crizotinib: aseptic abscesses in multiple organs during treatment of EML4-ALK-positive NSCLC.
     J Cancer Res Clin Oncol. 2021;147:3769-3771.
     PubMed     Abstract available
     
     
     
293. WU H, Zhang Y, Hu H, Li Y, et al
     Ground glass opacity featured lung adenocarcinoma in teenagers.
     J Cancer Res Clin Oncol. 2021;147:3719-3724.
     PubMed     Abstract available
     
     
     
294. NOMURA K, Aokage K, Nakai T, Sakashita S, et al
     Prognostic impact of extranodal extension in patients with pN1-N2 lung adenocarcinoma.
     J Cancer Res Clin Oncol. 2021;147:3699-3707.
     PubMed     Abstract available
     
     
     
295. UEDA D, Ito M, Tsutani Y, Gimenez-Capitan A, et al
     Comprehensive analysis of the clinicopathological features, targetable profile, and prognosis of mucinous adenocarcinoma of the lung.
     J Cancer Res Clin Oncol. 2021;147:3709-3718.
     PubMed     Abstract available
     
     
     November 2021
296. NEUMANN JM, Freitag H, Hartmann JS, Niehaus K, et al
     Subtyping non-small cell lung cancer by histology-guided spatial metabolomics.
     J Cancer Res Clin Oncol. 2021 Nov 28. pii: 10.1007/s00432-021-03834.
     PubMed     Abstract available
     
     
     
297. NAKAMURA R, Yamada T, Morimoto K, Nakao A, et al
     Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients.
     J Cancer Res Clin Oncol. 2021 Nov 26. pii: 10.1007/s00432-021-03866.
     PubMed     Abstract available
     
     
     
298. WANG P, Yin T, Zhao K, Yu J, et al
     Efficacy of single-site radiotherapy plus PD-1 inhibitors vs PD-1 inhibitors for oligometastatic non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2021 Nov 23. pii: 10.1007/s00432-021-03849.
     PubMed     Abstract available
     
     
     
299. CHEN Q, Li Y, Zhang W, Wang C, et al
     Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study.
     J Cancer Res Clin Oncol. 2021 Nov 19. pii: 10.1007/s00432-021-03858.
     PubMed     Abstract available
     
     
     
300. GAO X, Peng L, Zhang L, Huang K, et al
     Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer.
     J Cancer Res Clin Oncol. 2021 Nov 8. pii: 10.1007/s00432-021-03848.
     PubMed     Abstract available
     
     
     
301. FANG X, Wu G, Hua J, Zhao P, et al
     TCF-1(+) PD-1(+) CD8(+)T cells are associated with the response to PD-1 blockade in non-small cell lung cancer patients.
     J Cancer Res Clin Oncol. 2021 Nov 2. pii: 10.1007/s00432-021-03845.
     PubMed     Abstract available
     
     
     
302. UHLENBRUCH M, Kruger S
     Effect of antimicrobial therapy on progression-free survival of patients with non-small cell lung cancer receiving checkpoint inhibitor- and chemotherapy.
     J Cancer Res Clin Oncol. 2021 Nov 1. pii: 10.1007/s00432-021-03734.
     PubMed     Abstract available
     
     
     
303. CUI K, Mei X, Cheng M
     Increased interleukin-17A-producing gammadeltaT cells predict favorable survival in elderly patients with LUAD and LUSC.
     J Cancer Res Clin Oncol. 2021;147:3289-3298.
     PubMed     Abstract available
     
     
     
304. GAO Z, Han H, Zhao Y, Yuan H, et al
     A tumor microenvironment-related mRNA-ncRNA signature for prediction early relapse and chemotherapeutic sensitivity in early-stage lung adenocarcinoma.
     J Cancer Res Clin Oncol. 2021;147:3195-3209.
     PubMed     Abstract available
     
     
     
305. WANG YJ, Wang QW, Yu DH, Song CK, et al
     Osteopontin improves sensitivity to tyrosine kinase inhibitor in lung adenocarcinoma in vitro by promoting epidermal growth factor receptor phosphorylation.
     J Cancer Res Clin Oncol. 2021;147:3245-3254.
     PubMed     Abstract available
     
     
     October 2021
306. BAI R, Chen X, Song W, Tian H, et al
     Therapeutic exploration of uncommon EGFR exon 20 insertion mutations in advanced non-small cell lung cancer: breaking through brambles and thorns.
     J Cancer Res Clin Oncol. 2021 Oct 26. pii: 10.1007/s00432-021-03840.
     PubMed     Abstract available
     
     
     
307. ZHOU L, Wang X, Lu J, Fu X, et al
     EGFR transcriptionally upregulates UTX via STAT3 in non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2021 Oct 18. pii: 10.1007/s00432-021-03800.
     PubMed     Abstract available
     
     
     
308. ZHAO Y, Wang H, He C
     Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy.
     J Cancer Res Clin Oncol. 2021 Oct 18. pii: 10.1007/s00432-021-03828.
     PubMed     Abstract available
     
     
     
309. ZENG J, Li X, Liang L, Duan H, et al
     Phosphorylation of CAP1 regulates lung cancer proliferation, migration, and invasion.
     J Cancer Res Clin Oncol. 2021 Oct 12. pii: 10.1007/s00432-021-03819.
     PubMed     Abstract available
     
     
     September 2021
310. ROCHA ALG, da Conceicao MAM, da Cunha Sequeira Mano FXP, Martins HC, et al
     Metabolic active tumour volume quantified on [(18)F]FDG PET/CT further stratifies TNM stage IV non-small cell lung cancer patients.
     J Cancer Res Clin Oncol. 2021 Sep 27. pii: 10.1007/s00432-021-03799.
     PubMed     Abstract available
     
     
     
311. TANG X, Li Y, Qian WL, Yan WF, et al
     A comprehensive prognostic analysis of osimertinib treatment in advanced non-small cell lung cancer patients with acquired EGFR-T790M mutation: a real-world study.
     J Cancer Res Clin Oncol. 2021 Sep 18. pii: 10.1007/s00432-021-03797.
     PubMed     Abstract available
     
     
     
312. ZHONG Y, Wu Q, Wu S, Xie X, et al
     Comparing strategy of immune checkpoint inhibitors plus chemotherapy with chemotherapy alone for small cell lung cancer: a meta-analysis based on six RCTs incorporating 2800 participants.
     J Cancer Res Clin Oncol. 2021 Sep 17. pii: 10.1007/s00432-021-03798.
     PubMed     Abstract available
     
     
     
313. OMORI S, Muramatsu K, Kawata T, Miyawaki E, et al
     Trophoblast cell-surface antigen 2 expression in lung cancer patients and the effects of anti-cancer treatments.
     J Cancer Res Clin Oncol. 2021 Sep 17. pii: 10.1007/s00432-021-03784.
     PubMed     Abstract available
     
     
     
314. POMPILI C, Dalmia S, McLennan Battleday F, Rogers Z, et al
     Factors influencing patient satisfaction after treatments for early-stage non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2021 Sep 13. pii: 10.1007/s00432-021-03795.
     PubMed     Abstract available
     
     
     
315. MORIMOTO K, Uchino J, Yokoi T, Kijima T, et al
     Early discontinuation of induction therapy in chemoimmunotherapy as an effective alternative to the standard regimen in patients with non-small cell lung cancer: a retrospective study.
     J Cancer Res Clin Oncol. 2021 Sep 12. pii: 10.1007/s00432-021-03782.
     PubMed     Abstract available
     
     
     
316. KASHIWABARA K, Fujii S, Tsumura S, Sakamoto K, et al
     Efficacy and safety of transbronchial microwave ablation therapy under moderate sedation in malignant central airway obstruction patients with respiratory failure: a single-institution retrospective study.
     J Cancer Res Clin Oncol. 2021;147:2751-2757.
     PubMed     Abstract available
     
     
     
317. GROGG JB, Fronzaroli JN, Oliveira P, Bode PK, et al
     Clinicopathological characteristics and outcomes in men with mesothelioma of the tunica vaginalis testis: analysis of published case-series data.
     J Cancer Res Clin Oncol. 2021;147:2671-2679.
     PubMed     Abstract available
     
     
     August 2021
318. WANG F, Jin F, Cheng B, Zhang Y, et al
     The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2021 Aug 6. pii: 10.1007/s00432-021-03752.
     PubMed     Abstract available
     
     
     
319. IANZA A, Di Chicco A, Biagi C, Giudici F, et al
     EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience.
     J Cancer Res Clin Oncol. 2021;147:2301-2307.
     PubMed     Abstract available
     
     
     
320. LI P, Hou F, Wang S, Luo N, et al
     A novel NECTIN4-NTRK1 fusion identified in a lung squamous cell carcinoma patient with MSI-H.
     J Cancer Res Clin Oncol. 2021;147:2483-2486.
     PubMed    
     
     
     July 2021
321. HIZAL M, Bilgin B, Paksoy N, Acikgoz O, et al
     The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study.
     J Cancer Res Clin Oncol. 2021 Jul 31. pii: 10.1007/s00432-021-03748.
     PubMed     Abstract available
     
     
     
322. YANG Z, Yu R, Deng W, Wang W, et al
     Genetic evidence for the causal association between programmed death-ligand 1 and lung cancer.
     J Cancer Res Clin Oncol. 2021 Jul 29. pii: 10.1007/s00432-021-03740.
     PubMed     Abstract available
     
     
     
323. SU Z, Jiang Y, Li C, Zhong R, et al
     Relationship between lung function and lung cancer risk: a pooled analysis of cohorts plus Mendelian randomization study.
     J Cancer Res Clin Oncol. 2021 Jul 27. pii: 10.1007/s00432-021-03619.
     PubMed     Abstract available
     
     
     
324. OTA T, Kirita K, Matsuzawa R, Udagawa H, et al
     Correction to: Validity of using immunohistochemistry to predict treatment outcome in patients with non-small cell lung cancer not otherwise specified.
     J Cancer Res Clin Oncol. 2021 Jul 23. pii: 10.1007/s00432-021-03737.
     PubMed    
     
     
     
325. SUN J, Zhang J, Hu H, Qin H, et al
     Anti-tumour effect of neo-antigen-reactive T cells induced by RNA mutanome vaccine in mouse lung cancer.
     J Cancer Res Clin Oncol. 2021 Jul 21. pii: 10.1007/s00432-021-03735.
     PubMed     Abstract available
     
     
     
326. BRANCHER S, Ribeiro AE, Toporcov TN, Weiderpass E, et al
     The role of metformin on lung cancer survival: the first systematic review and meta-analysis of observational studies and randomized clinical trials.
     J Cancer Res Clin Oncol. 2021 Jul 15. pii: 10.1007/s00432-021-03728.
     PubMed     Abstract available
     
     
     
327. GUO R, Zhang Y, Ma Z, Deng C, et al
     Overuse of follow-up chest computed tomography in patients with incidentally identified nodules suspicious for lung cancer.
     J Cancer Res Clin Oncol. 2021 Jul 8. pii: 10.1007/s00432-021-03692.
     PubMed     Abstract available
     
     
     
328. HE X, Ma X, Wang C, Luan M, et al
     The peptide mimicking small extracellular ring domain of CD82 inhibits tumor cell migration in vitro and metastasis in vivo.
     J Cancer Res Clin Oncol. 2021;147:1927-1934.
     PubMed     Abstract available
     
     
     
329. LIU J, Hao J, Niu Y, Wu X, et al
     Network pharmacology-based and clinically relevant prediction of active ingredients and potential targets of Chinese herbs on stage IV lung adenocarcinoma patients.
     J Cancer Res Clin Oncol. 2021;147:2079-2092.
     PubMed     Abstract available
     
     
     June 2021
330. DOU Y, Duan Q, Qi C, Hou L, et al
     An intergenic region ALK fusion identified by DNA sequencing and validated by IHC in an early-stage lung adenocarcinoma.
     J Cancer Res Clin Oncol. 2021;147:1865-1867.
     PubMed     Abstract available
     
     
     May 2021
331. SHEN Z, Chen C, Sun J, Huang J, et al
     The status of WIF1 methylation in cell-free DNA is associated with the insusceptibility for gefitinib in the treatment of lung cancer.
     J Cancer Res Clin Oncol. 2021 May 26. pii: 10.1007/s00432-021-03640.
     PubMed     Abstract available
     
     
     
332. ZHANG Y, Zhang Z, Ding Y, Fang Y, et al
     Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed/refractory non-small cell lung cancer patients.
     J Cancer Res Clin Oncol. 2021 May 25. pii: 10.1007/s00432-021-03613.
     PubMed     Abstract available
     
     
     
333. ZHAO Y, Liu Y, Li S, Peng Z, et al
     Role of lung and gut microbiota on lung cancer pathogenesis.
     J Cancer Res Clin Oncol. 2021 May 20. pii: 10.1007/s00432-021-03644.
     PubMed     Abstract available
     
     
     
334. DAI Y, Zhong F, Liu W, Song Q, et al
     Mycoplasma hyorhinis infection promotes tyrosine kinase inhibitor (TKI) resistance in lung adenocarcinoma patients.
     J Cancer Res Clin Oncol. 2021;147:1379-1388.
     PubMed     Abstract available
     
     
     
335. FRANZESE C, Badalamenti M, Teriaca A, De Virgilio A, et al
     Metastasis-directed stereotactic body radiation therapy in the management of oligometastatic head and neck cancer.
     J Cancer Res Clin Oncol. 2021;147:1307-1313.
     PubMed     Abstract available
     
     
     April 2021
336. LEONETTI A, Carbone D, Gregori A, Tiseo M, et al
     A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients?
     J Cancer Res Clin Oncol. 2021 Apr 26. pii: 10.1007/s00432-021-03647.
     PubMed    
     
     
     
337. QIU X, Zhang H, Zhao Y, Zhao J, et al
     Application of circulating genetically abnormal cells in the diagnosis of early-stage lung cancer.
     J Cancer Res Clin Oncol. 2021 Apr 24. pii: 10.1007/s00432-021-03648.
     PubMed     Abstract available
     
     
     
338. NOUNU A, Walker V, Richmond RC
     Correction to: Letter regarding, "Association between the use of aspirin and risk of lung cancer: results from pooled cohorts and Mendelian randomization analyses".
     J Cancer Res Clin Oncol. 2021 Apr 11. pii: 10.1007/s00432-021-03636.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.